

## AUTHOR INDEX

- Agarwal, R., 479  
 Ahya, S. N., 507  
 Ansarin, K., 71  
 Ash, S. R., 221
- Baran, A. S., 71  
 Battle, D., 439, 494, 526  
 Beathard, G. A., 202  
 Boner, G., 393  
 Brenner, K., 89  
 Brown, N. J., 399
- Cain, A. E., 3  
 Campistol, J. M., 361, 365  
 Carr, F. J., 127  
 Carswell, H. V. O., 127  
 Charchar, F. J., 127  
 Colucci, P., 309  
 Cooper, M. E., 393  
 Crook, E. D., 27
- Davis, M. M., 35  
 DeBlois, D., 161  
 Dhingra, H., 423  
 Dominguez-Gil, B., 365  
 Dominiczak, A. F. D., 127
- Epstein, M., 391  
 Esforzado, N., 361
- Fabrizi, F., 309  
 Ferrell, L. M., 195  
 Fishbane, S., 407, 474  
 Fogo, A. B., 399  
 Fontaine, H., 331
- Gallon, L. G., 515  
 Ghossein, C., 439, 526  
 Girndt, M., 340  
 Gomez-Sanchez, C. E., 44  
 Graham, D., 127  
 Gross, V., 172
- Hamann, A., 100  
 Hamet, P., 161  
 Ho, L. T., 268, 488  
 Hoegerle, S., 89  
 Hörl, W. H., 287, 290  
 Hübner, N., 135
- Iliopoulos, O., 89  
 Inoue, C. N., 415  
 Isler, C. M., 54
- Jaradat, M. I., 459  
 Jones, D. W., 35
- Kaufman, D. B., 515  
 Kausz, A. T., 441  
 Khalil, R. A., 3  
 Khosla, N., 507  
 Kimmel, P. L., 449  
 Kletzmayer, J., 375  
 Köhler, H., 340  
 Korbet, S. M., 254  
 Kramer, L., 290  
 Kreutz, R., 135  
 Kshirsagar, A., 494  
 Kurtz, T. W., 148  
 Kurtzman, N. A., 423
- Lebray, P., 331  
 Leventhal, J. R., 515  
 Lhotta, K., 302  
 Locatelli, F., 309, 319  
 Lufi, F. C., 79, 81, 115, 172  
 Gross, V., 172
- McBride, M. W., 127  
 Macrae, I. M., 127  
 Maesaka, J. K., 407  
 Manz, T., 89  
 Martin, J. N., Jr., 54  
 Meeks, W. M., 65  
 Molitoris, B. A., 459  
 Moneva, M. H., 44  
 Morales, J. M., 361, 365  
 Mundel, P., 393
- Neumann, H. P. H., 89  
 Nothnagel, M., 105
- Obrador, G. T., 441  
 O'Neill, W. C., 181, 242  
 Orlov, S. N., 161  
 Ott, J., 105
- Palaia, T., 407  
 Paparello, J., 494  
 Patel, S. S., 449  
 Paulson, W. D., 183  
 Pereira, B. J. G., 441  
 Perry, M. A., 195  
 Pol, S., 331  
 Ponticelli, C., 309
- Pozzi, C., 319  
 Pravenec, M., 148  
 Puttinger, H., 351
- Ragolia, L., 407  
 Ram, S. J., 183  
 Rammohan, M., 526  
 Rasmussen, R. L., 237  
 Richert, A., 71  
 Roongsritong, C., 423  
 Ryan, M. J., 154
- Saad, T. F., 276  
 Salem, M. M., 1, 17  
 Sands, J. J., 195  
 Serrano, A., 526  
 Sharma, A. M., 100  
 Sigmund, C. D., 154  
 Singh, A., 449  
 Sprague, S. M., 268, 488
- Toka, H. R., 81  
 Tremblay, J., 161
- Vallet-Pichard, A., 331  
 Vaughan, D. E., 399  
 Vychtil, A., 351
- Warnock, D., 479  
 Watschinger, B., 375  
 Work, J., 211
- Zibari, G. B., 183

## SUBJECT INDEX

- AAT ( $\alpha_1$ -antitrypsin) deficiency in GN, 306-307  
 ABO blood group determination, pre-RTX, in RTX candidates with CKD, 519  
 Acarbose, 498  
 Access  
   to AVGs prior to angioplasty, 206  
   *see also* Vascular access  
 Access center, *see* Dialysis access center  
 Accreditation of interventional nephrology training programs, 277  
 Accuracy  
   of anatomic imaging of vascular access with color flow Doppler ultrasound, 197  
    $Q_a$  decrease over 3 months and  $Q_a$  measurement, as predictors of vascular access thrombosis, 191  
 ACE, *see* Angiotensin-converting enzyme inhibitors for hypertension  
 N-Acetylcysteine, 298  
 Acquired apparent mineralocorticoid excess (AME), HTN in, 49
- Action plan, clinical, for CKD, 447  
 Active vaccination against HBV infection, 344-347  
 Acute hemodynamic consequences of OSA, 72-73  
 Acute tubular necrosis with HRS, 295-296  
 1-Acyl-sn-glycerol-3-phosphate, *see* Lysophosphatidic acid in mesangial cell proliferation and apoptosis  
 Additive transgenesis, described, 154-156  
 Adducin in HTN, 117-118  
 Adefovir dipivoxil, 385  
 Adenoma, aldosterone-producing, HTN in, 46, 47  
 Adrenal hypertension (HTN), 44-53  
   in AME, *see* Apparent mineralocorticoid excess, HTN in  
   in cortisol biosynthesis disorders, 48  
   in GRA, *see* Glucocorticoid-remediable aldosteronism, HTN in  
   of MCH, *see* Mineralocorticoid hypertension  
   nonepithelial action of corticosteroids in, 44-45  
   in PA, 45-47  
 $\alpha$  (alpha)-Adrenergic agonists, 297  
 $\alpha$  (alpha)-Adrenergic blockers, 96

- $\beta$  (beta)-Adrenergic blockers, 67, 69, 84, 96
- $\alpha$  (alpha) and  $\beta$  (beta)-Adrenergic receptors, role of, in sympathetic tone, HTN and, 119-120
- Advantages, *see* Benefits
- Adverse reactions to IV iron preparations, 482-485
- Aging, accelerated cell cycle, HTN and, 163-164; *see also* Elderly, the, HTN in
- Airway obstruction, upper, due to ongoing respiratory effort in OSA, 72-73
- AL, *see* Amyloid light-chain amyloidosis
- Albumin dialysis (Molecular Adsorbent Recirculating System) for HRS, 298
- Alcohol intake, HTN prevention and management with reduced, 38-39
- Aldosterone, *see* Aldosterone-producing adenoma; Glucocorticoid-remediable aldosteronism, HTN in; Hyperaldosteronism; Liddle's syndrome-associated hypertension; Renin-angiotensin-aldosterone system
- Aldosterone-producing adenoma (APA), HTN in, 46, 47
- Alfacalcidol, 492-493
- ALG (antilymphocyte globulin), 370
- Allograft, renal
- chronic HBV infection-related damage to, 378; *see also* Chronic hepatitis B virus infection, RTX and HCV infection and survival of, 369
- Alpha ( $\alpha$ )-adrenergic agonists, 297
- Alpha ( $\alpha$ )-adrenergic blockers, 96
- 11 Alpha ( $\alpha$ )-adrenergic receptors, role of, in sympathetic tone, HTN and, 119-120
- Alpha ( $\alpha$ )-tocopherol (vitamin E) supplementation, 58, 469
- Ambulatory peritoneal dialysis, *see* Continuous ambulatory peritoneal dialysis
- AME, *see* Apparent mineralocorticoid excess, HTN in
- Amiloride, 29, 82
- Aminoglycosides, 292
- Amyloid light-chain (AL) amyloidosis, 319-327
- liver involvement in, 323-325
  - renal involvement in, 321-322
  - therapy of, 325-327
- Anatomic criteria applied to balloon angioplasty outcome, 208
- Anatomic imaging of vascular access with color flow Doppler ultrasound, accuracy of, 197
- Anatomy of AVF, 183
- Anemia, rHuEPO therapy of
- dialysis dementia, 412-413
  - and HBV infection in HD patients, 346
  - in renal hypertension, 22-23
  - see also* Anemia in CKD, rHuEPO therapy of; Anemia in CRI, rHuEPO therapy of
- Anemia in CKD, rHuEPO therapy of
- anemia as risk factor for CVD with CKD and, 463-466, 469
  - in comprehensive care clinic, 527-528
  - iron-deficiency anemia, 479, 481, 482
- Anemia in CRI, rHuEPO therapy of, 474-478
- benefits of rHuEPO, 474-475
  - etiology of, 474
  - frequency of rHuEPO dosing, 475-476
  - hemoglobin level and therapy initiation, 475-476
  - monitoring, 476
  - reimbursement of, 476
  - risks of, 475
  - screening for anemia and, 474
  - starting rHuEPO dose, 476
- Angioplasty (percutaneous transluminal angioplasty; balloon angioplasty) for AVF and AVGs, 202-210
- for AVG stenosis, 203-205
  - complications of, 208-209
  - for early and late AVF failure, 202-203
  - hemostasis in, 209
  - standard technique of, 207-208
  - steps prior to, 205-207
  - training requirements for, 209-210
- Angiotensin, *see* Angiotensin-converting enzyme inhibitors for hypertension; Renin-angiotensin-aldosterone system
- Angiotensin-converting enzyme (ACE) inhibitors for hypertension
- in CVD with CKD, 496-498, 501
  - in diabetic nephropathy, 32
  - in the elderly, 69
  - in essential hypertension, 30
  - in monogenic hypertension, 84
- Angiotensin II receptor blockers (ARBs), 467, 469, 496-498
- ANP, *see* Atrial natriuretic peptide
- Antibiotics, 216
- Antibodies to HLA phenotypes, serum screening for, in pre-RTX evaluation of CKD patients, 520
- Anti-hepatitis C virus (HCV)-positive kidney donors for RTX in HCV-infected patients, 370-372
- Antihypertensive drug therapy
- for renal failure-associated HTN, 17, 20-22
  - see also* Hypertension, pathophysiology of and specific antihypertensive agents
- Anti-inflammatory effects of estrogens, stroke and, 132
- Antilymphocyte globulin (ALG), 370
- Antioxidant(s), 468, 469
- Antioxidant effects of estrogens, stroke and, 132
- Antioxidant nutrients in preeclampsia management, 58
- Antithymocyte globulin (ATG), 370
- $\alpha$  ( $\alpha$ )<sub>1</sub>-Antitrypsin (AAT) deficiency in GN, 306-307
- APA (aldosterone-producing adenoma), HTN in, 46, 47
- Apnea, *see* Obstructive sleep apnea-related hypertension
- Apoptosis (programmed cell death) and proliferation in HTN, 161-171
- aging, accelerated cell cycle and, 163-164
  - candidate gene approach to, 164-165
  - exaggerated apoptosis, 162-163
  - phenotypes of exaggerated proliferation, 161-162
  - total genome scan in, 165-167
- Apoptosis (programmed cell death) in renal disease and progression of chronic renal failure, 409-410
- see also* Lysophosphatidic acid in mesangial cell proliferation and apoptosis
- Apoptotic time windows, defined, 163
- Apparent mineralocorticoid excess (AME), HTN in
- monogenic HTN in, 28, 29, 82-84, 86
  - pathophysiology of, 46, 48-50
- Aquaretic agents, 297
- Arachidonic acid, role of, in vascular smooth muscle contractions, essential HTN and, 10-11
- ARBs (angiotensin II receptor blockers), 467, 469, 496-498
- Arterial stenosis, *see* Stenosis, AVF; Stenosis, AVG
- Arterial vasodilation hypothesis of Na retention, 292-293

- Arteriopathy with subcortical infarcts and leukoencephalopathy, cerebral autosomal-dominant, 128
- Arteriovenous fistulae (AVF)
- anatomy of, 183
  - angioplasty for early and late failure of, 202-203; *see also* Angioplasty for AVF and AVGs
  - complications of, 187-188
  - creating additional, 186-187
  - physical examination of, 185
  - placement of, *see* Placement of AVF
  - post-PRB, 264
  - see also* Dialysis access in CKD; Stenosis, AVF; Vascular access
- Arteriovenous grafts (AVGs; polytetrafluoroethylene grafts; synthetic grafts)
- angioplasty for stenosis of, 203-205; *see also* Angioplasty for AVF and AVGs; Stenosis, AVG
  - complications of, 187-188
  - physical examination of, 185
  - placement of, 187
  - thrombosis of, *see* Thrombosis, AVG
  - see also* Dialysis access in CKD; Vascular access
- Ascites in HRS, 291-293
- formation of, 292-293
  - prognosis of, 291
- Ascorbic acid (vitamin C) supplementation, 58, 469
- Aspirin, 468, 469
- Association analysis of trait gene mapping, 106, 116
- Atenolol, 21
- ATG (antithymocyte globulin), 370
- Atrial natriuretic peptide (ANP)
- function of, 424-425
  - in HTN, 120
- Atropine, 20
- Autosomal-dominant arteriopathy, cerebral, with subcortical infarcts and leukoencephalopathy, 128
- Autosomal-dominant hypertension (HTN) with brachydactyly, as monogenic form of HTN, 84-87
- AVF, *see* Arteriovenous fistulae
- AVGs, *see* Arteriovenous grafts
- Azathioprine, 367, 381
- Balloon angioplasty, *see* Angioplasty for AVF and AVGs
- Balloon catheters
- selection of, 206
  - see also* Angioplasty for AVF and AVGs
- Barter's syndrome, 29
- Benefits
- of iron replacement in iron-deficiency anemia of CKD, 480
  - of K/DOQI CKD guidelines, 455-456
  - of rHuEPO therapy of anemia in CRI, 474-475
- Berger's disease, *see* IgA nephropathy
- Beta ( $\beta$ )-adrenergic blockers, 67, 69, 84
- Beta ( $\beta$ )-adrenergic receptors, role of, in sympathetic tone, HTN and, 119-120
- Beta ( $\beta$ )-carotene supplementation in preeclampsia, 58
- 11Beta ( $\beta$ )-hydroxylase deficiency-associated hypertension (HTN), 46-48
- 17Beta ( $\beta$ )-hydroxylase deficiency-associated hypertension (HTN), 46-48
- 11Beta ( $\beta$ )-hydroxysteroid dehydrogenase (HSD) gene in HTN, 46, 117-118
- Billing for renal and urinary tract ultrasound, 251
- Bimodal effects of PDGF on mesangial cell proliferation and apoptosis, 416-417
- Biochemical markers of ROS, 270
- Biofeedback, HTN prevention and management with, 39
- Biology of nephrin, new directions in, 396
- Biopsy, *see* Percutaneous bone biopsy in ROS; Percutaneous renal biopsy
- Birth weight, and renal failure-associated HTN, 23
- Bisoprolol, 21
- Blind puncture method of chronic PD catheter placement, 225-227
- Blood flow ( $Q_a$ )
- cerebral, in stroke, estrogen effects on, 132
  - see also* Blood flow, vascular access
- Blood flow ( $Q_a$ ), vascular access
- measurements of, 190
  - see also* Stenosis, AVF; Stenosis, AVG; Thrombosis, vascular access
- Blood group determination, pre-renal transplant ABO, of RTX candidates with CKD, 519
- Blood pressure
- measurement of, 173-174
  - see also* Blood pressure loci; Hypertension, as complex trait; Hypertension, pathophysiology of
- Blood pressure loci, linkage analysis of statistical gene mapping for new, 120-123
- BNP, *see* Brain natriuretic peptide, role of
- Body weight
- at birth, and renal failure-associated HTN, 23
  - loss of, HTN prevention with, 37-38
  - see also* entries beginning with term: Obesity
- Bone biopsy, *see* Percutaneous bone biopsy in ROS
- BQ123, 298
- Brachydactyly, autosomal-dominant HTN with, 84-87
- Brain natriuretic peptide (BNP), role of, 423-437
- and ANP function, 424-425
  - cardiovascular actions of, 426-429
  - central nervous system actions of, 431-432
  - characteristics of, 425
  - CNP function and, 425-426
  - miscellaneous actions of, 432
  - natriuretic peptide receptor function and, 426
  - renal actions of, 430-431
- Breeding, congenic, strategies for, 139-140
- Burying of chronic PD catheter, catheter outcome and, 233
- Button hole, described, 218
- Ca (calcium) channel blockers, 21, 467
- Ca<sup>2+</sup> (calcium)-dependent myosin light chain (MLC), role of, in vascular smooth muscle contractions, essential HTN and, 8-9
- Ca (calcium)-phosphate metabolism, abnormal, as risk factor for CVD in CKD, 467-468
- Ca (calcium) supplementation, 39, 491, 492
- CADASIL (cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy), 128
- Calcimimetics, 467
- Calcitriol in ROS, 491-493

- Calcium. *see* Ca channel blockers;  $\text{Ca}^{2+}$ -dependent myosin light chain; Ca supplementation; Calcimimetics; Calcium-phosphate metabolism; Hypercalcemia
- Candidate gene(s) in HTN  
for apoptosis and proliferation, 164-165  
for essential HTN, 145  
for syndrome X, *Cd36* as, 149-150; *see also: Cd36* in syndrome X
- Candidate(s) to RTX  
epidemiology of chronic HBV infection in, 375  
*see also* Pre-renal transplant evaluation of RTX candidates with CKD
- Cannulation site for angioplasty of AVF and AVGs, 206
- CAPD. *see* Continuous ambulatory peritoneal dialysis
- Carbenoxolone and licorice ingestion, HTN due to, 45, 46
- Cardiac function, genetic HTN and, 176-178
- Cardiovascular disease (CVD)  
pre-existing, pre-RTX evaluation of, in CKD patients, 517  
*see also* Cardiovascular disease with CKD
- Cardiovascular disease (CVD) with CKD, 459-473  
during predialysis period, 461-462  
risk factors for. *see* Risk factor(s) for CVD with CKD  
stratification of risk for development of, in K/DOQI guidelines, 453-454
- Cardiovascular homeostasis, BNP and, 426-429
- Cardiovascular physiology. *see* Renal and cardiovascular physiology
- Cardiovascular and renal mediators. *see* Naturally occurring cardiovascular and renal mediators
- Cardiovascular system  
aging changes in, 68  
BNP actions on, 426-429  
physiology of. *see* Renal and cardiovascular physiology  
*see also* Heart; Heart failure entries beginning with terms: Cerebral, Vascular and element: Card-
- $\beta$  (beta)-Carotene supplementation, 58
- Carriers of germline mutations, genes predisposing to pheochromocytoma in, 95-96
- Catheters  
selection of balloon, for angioplasty of AVF and AVGs, 206  
*see also* Chronic peritoneal dialysis catheters; Cuffed, tunneled catheters
- CBF (cerebral blood flow), estrogen effects on, stroke and, 132
- CCPD (continuous cycling peritoneal dialysis), HBV and/or HCV infection in patients on, 352
- Cd36* in syndrome X (hypertension metabolic syndrome), 148-153  
chromosome region linked to, 149  
effects of transgenic rescue of, 151  
insulin resistance and fatty acid metabolism and, 150-152  
QTL of. *see* Quantitative trait loci mapping of defective *Cd36* in syndrome X  
relevance of, 152
- Cell cycle, accelerated, aging and, 163-164
- Cell death. *see* entries beginning with term: Apoptosis
- Cell survival, mesangial, LPA effects on, 417-418
- Cellular proliferation. *see* Apoptosis and proliferation in HTN; Lysophosphatidic acid in mesangial cell proliferation and apoptosis
- Central nervous system actions of BNP, 431-432
- Cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), 128
- Cerebral blood flow (CBF) in stroke, estrogen effects on, 132
- Cerebrovascular disease. *see* Stroke, genetics of
- Certification for interventional nephrology practice  
for cuffed, tunneled catheter placement, 218-219, 280-281  
for monitoring chronic PD catheter placement, 235  
for renal and urinary tract ultrasound, 251-252  
training and, 278; *see also* Training in interventional nephrology
- Chemodectoma, defined, 89
- Cholestatic hepatitis. *see* Fibrosing cholestatic hepatitis
- Chromosome, consomics of Y, in stroke, 129-131
- Chromosome region linked to hypertension metabolic syndrome, 149
- Chronic hepatitis B virus (HBV) infection, RTX and, 375-385  
clinical relevance of HBV mutations in, 380-381  
epidemiology of, in candidates to and recipients of RTX, 375  
and evaluation of HBV-positive donor, 380  
immunosuppression and, 381  
influence of chronic HBV infection on RTX recipient mortality, 376-378  
post-RTX course of chronic HBV infection, 376  
pre-RTX patient evaluation and management, 379-380  
vaccination against, 383
- Chronic kidney disease (CKD)  
defined, 442  
introduction to, 439-440  
*see also* Anemia in CKD, rHuEPO therapy of; Cardiovascular disease with CKD; Clinical practice guidelines, K/DOQI CKD; Dialysis access in CKD; Iron-deficiency anemia in CKD; Pre-renal transplant evaluation of RTX candidates with CKD; Renal osteodystrophy in CKD; Stabilization of CKD, role of comprehensive renal care clinic in; United States, CKD in
- Chronic peritoneal dialysis (PD) catheters, 221-236  
burying, 229-233  
outcome of. *see* Successful outcome of chronic PD catheters placement of. *see* Placement of chronic PD catheters  
removal of, 233-235
- Chronic renal failure (end-stage renal disease). *see* Chronic kidney disease; Prostaglandin  $\text{D}_2$  synthase, progression of chronic renal failure and; Renal failure-associated hypertension
- Chronic renal insufficiency. *see* Anemia in CRI, rHuEPO therapy of
- Circulating factor X, role of, in preeclampsia, 59
- Circulating syncytiotrophoblast, role of, in preeclampsia, 59
- CKD. *see* Chronic kidney disease
- Classification  
of CKD, 447  
of CKD stages in K/DOQI guidelines, 450-451  
of cryoglobulinemias, 309-310  
of ROS, 270, 490
- Clinical action plan for CKD, 447
- Clinical course  
of HCV infection, 366  
post-RTX chronic HBV infection, 376
- Clinical criteria applied to angioplasty outcome, 208
- Clinical features and presentation  
of AVG stenosis, 188

- of cryoglobulinemic GN, 311-312
  - see also specific conditions*
- Clinical practice guidelines (CPGs), K/DOQI CKD, 448-458
- CPGs defined, 454
  - definition and classification of CKD stages in, 450-451
  - essential aspects of, 454-455
  - evaluation of laboratory measurement for CKD in, 451-453
  - and GFR level associated with complications of CKD, 453
  - history of K/DOQI and, 449-450
  - limitations and advantages of, 455-456
  - stratification of risk for progression of renal disease and CVD development in, 453-454
- Clinical significance of GN, 303-304
- Clone contig construction method, 144-145
- Cloning, positional, defined, 138
- CNP (C-type natriuretic peptide), function of, 425-426
- Coagulopathies, pre-existing, in CKD patients, pre-RTX evaluation of, 518
- Color flow Doppler ultrasound of vascular access, 195-201
  - dysfunctional access identification with, 197-198
  - financial implications of, 198
  - interpretation of data from, 200
  - monitoring with, 190-191, 195-196
  - the procedure, 200
  - reimbursement of, 199-200
- Combined dietary approaches to HTN prevention and management, 40-41
- Competence, *see* Knowledge, skills, and competence in interventional nephrology procedures
- Complementary determining regions in monoclonal LC disorders, 320
- Complete linkage in recombination, 105
- Complex trait(s)
  - HTN as, *see* Hypertension, as complex trait
  - statistical gene mapping of, 110-112
- Complications
  - extrahepatic, of HCV infection in HD patients, 333
  - of percutaneous bone biopsy, 274
  - of PRB, 258, 260-264
  - see also* Complications, CKD; Complications, vascular access *specific conditions and procedures*
- Complications, CKD
  - of dialysis access, 511-512
  - GFR level associated with, 453
  - management of, and disease stabilization, 527-528
  - see also specific complications of CKD*
- Complications, vascular access, 187-188
  - of angioplasty for AVF and AVGs, 208-209
  - of chronic PD catheters, placement method and, 227
  - in CKD, 511-512
  - of cuffed, tunneled catheters, 213-214
  - see also specific complications of vascular access*
- Computed tomography (CT) in PRB, 259
- Congenetic breeding, *see* Essential hypertension, genetics of
- Congenital apparent mineralocorticoid excess (type I AME), HTN in, 48-49
- Congestive heart failure, BNP in, 427-429
- Consomics, Y chromosome, in stroke, 129-131
- Continuous ambulatory peritoneal dialysis (CAPD)
  - HBV and/or HCV infection in patients on, 352, 356
  - for monoclonal LC disorders, 326
  - see also* Chronic peritoneal dialysis catheters
- Continuous cycling peritoneal dialysis (CCPD), HBV and/or HCV infection in patients on, 352
- Continuous venovenous hemofiltration (CVVH) for HRS, 297, 298
- Contractions, smooth muscle, *see* Vascular smooth muscle contractions in essential HTN
- Contraindications
  - to living kidney donation, 522
  - to PRB, 255-256
  - to RTX, 516
  - see also specific conditions*
- Control strains in congenic breeding, 136
- Corticosteroids, 44-45, 314, 315
  - see also specific corticosteroids*
- Cortisol, 48, 49
- Cosegregation analysis of essential HTN, 137-138
- Cost of interventional nephrology procedures
  - of color flow Doppler ultrasound for vascular access, 198
  - see also* Billing for interventional nephrology procedures; Reimbursement of interventional nephrology procedures
- Course, *see* Clinical course
- COX2 (cyclooxygenase 2), renal, in progression of renal failure, 410-412
- CPGs, *see* Clinical practice guidelines, K/DOQI CKD
- Crash cart for emergencies in DAC, 239
- Creatinine, serum, in U.S. CKD patients, 442-443
- Credentials and privileges, hospital and facility, based on interventional nephrology training, 278-280
- Cre-loxP method, 157-158
- CRF (chronic renal failure), *see* Chronic kidney disease; Prostaglandin D<sub>2</sub> synthase, progression of chronic renal failure and; Renal failure-associated hypertension
- Cross-matching, pre-RTX, in RTX candidates with CKD, 520-521
- Cryoglobulin(s), defined, 307, 317
- Cryoglobulinemia(s), kidney and liver involvement in, 309-318
  - definition and classification, 309-310
  - see also* Cryoglobulinemic glomerulonephritis; Hepatitis C virus infection, cryoglobulinemia and; Mixed cryoglobulinemia
- Cryoglobulinemic glomerulonephritis (GN), 310-316
  - HCV infection and, 304-305
  - renal involvement in, 310-313
  - therapy of, 314-316
- CT (computed tomography) in PRB, 259
- C-type natriuretic peptide (CNP), function of, 425-426
- Cuffed, tunneled catheters, 211-219
  - insertion of, *see* Insertion of cuffed, tunneled catheters
  - outcome of, 217
  - placement of, *see* Cuffed, tunneled catheters, placement of
  - subcutaneous vascular ports as alternatives to, 217-218
  - types of, 216-217
- Cuffed, tunneled catheters, placement of, 217-219
  - certification for, 218-219
  - outcome of, 217
  - training for, 218-219, 280-281
  - see also* Insertion of cuffed, tunneled catheters
- Cushing's syndrome, HTN in, 46, 49
- CVD, *see* Cardiovascular disease

- CVVH (continuous venovenous hemofiltration) for HRS, 297, 298
- Cycling peritoneal dialysis, continuous, HBV and/or HCV infection in patients on, 352
- Cyclooxygenase 2 (COX2), renal, in progression of renal failure, 410-412
- Cyclophosphamide, 314, 316, 326
- Cyclosporine, 370, 381
- Cytokines, formation of, in preeclampsia, 58-59
- DAC, *see* Dialysis access center
- Darbapoietin, 475, 528
- Data collection for pre-RTX evaluation of RTX candidates with CKD, 516
- Death, *see* Mortality and entries beginning with term: Apoptosis
- Dementia, dialysis, PGD<sub>2</sub>S in, 412-413
- Design, chronic PD catheter, successful outcome and, 227-229
- Dexamethasone, 47-49, 326
- Diabetes mellitus, as risk factor for CVD in CKD, 498-499
- Diabetic nephropathy  
HTN associated with, 31-32  
nephrin in, 395
- Diagnosis  
of acute tubular necrosis in HRS, 295-296  
of AVG graft stenosis, 188  
of HBV and/or HCV infection in PD patients, 356  
of HRS, 290-292  
of iron-deficiency anemia in CKD, 480  
of pheochromocytoma, 89-91  
of ROS in CKD, 489-491; *see also* Percutaneous bone biopsy in ROS  
*see also* Diagnostic and interventional nephrology; Evaluation; Screening specific conditions and diagnostic techniques
- Diagnostic and interventional nephrology (procedural nephrology)  
introduction to, 181-182  
*see also* Certification for interventional nephrology practice; Percutaneous bone biopsy in ROS; Percutaneous renal biopsy; Training in interventional nephrology; Ultrasound in interventional nephrology procedures; Vascular access
- Dialysis, *see* Albumin dialysis; Chronic peritoneal dialysis catheters; Continuous ambulatory peritoneal dialysis; Hemodialysis; Hepatitis B and/or C virus infection in PD patients; Predialysis period and entries beginning with terms: Dialysis access
- Dialysis access center (DAC), 237-241  
conditions necessary for establishing, 237  
described, 237  
interventional nephrology training for working in, 237-238  
medical director of, 238  
operations manual of, 238-241
- Dialysis access in CKD, 507-514  
complications of, 511-512  
maturation of, 509-510  
planning, 507-509
- Dialysis dementia, PGD<sub>2</sub>S in, 412-413
- Diet, *see* Diet and lifestyle, HTN and; Dietary restriction; Nutrition
- Diet and lifestyle, HTN and  
contributions of, to HTN, 27  
*see also* Diet and lifestyle modification, HTN prevention and management with
- Diet and lifestyle modification, HTN prevention and management with, 35-43  
with alcohol intake reduction, 38-39  
with antioxidant nutrients in preeclampsia, 58  
with combined dietary approaches, 40-41  
with exercise, 38, 68  
with salt restriction, *see* Sodium restriction in HTN  
with stress management and biofeedback, 39  
with weight loss, 37-38
- Dietary restriction  
of Na, *see* Sodium restriction in HTN  
of phosphate in ROS, 491
- Dilation, sequential, of AVF, described, 202
- Dilation pressures in angioplasty of AVF and AVGs, 206
- Dimethylthiourea, 23
- Dissection method of chronic PD catheter placement, 224-225
- Diuresis-natriuresis-pressure measurements, 175-176
- Diuretics, 83, 467, 469
- Donors, *see* Living kidney donors
- Dopamine, 297, 298
- Doppler ultrasound, *see* Color flow Doppler ultrasound of vascular access
- Dose, starting rHuEPO, for anemia of CRI, 476
- Dosing frequency of rHuEPO for anemia in CRI, 475-476
- Doxorubicin (4'-iodo-4'-deoxy-doxorubicin), 326
- Duplex ultrasound of vascular access stenosis, 190
- Dynamic venous pressure (VP) in vascular access, measurement of, 189
- Early arteriovenous fistula (AVF) failure, angioplasty for, 202
- Early referral of CKD patients, CKD stabilization and, 527
- Early stages of CKD, epidemiology of CVD in, 494-495
- ECM (extracellular matrix), formation of, regulated by fibrinolytic system, 399
- EEG (electroencephalogram), arousal of, in OSA, 73
- Elderly, the, HTN in, 65-70  
and accelerated cell cycle due to aging, 163-164  
cardiovascular changes and, 68  
isolated systolic HTN, 67-68  
management of, 67-69  
systolic-diastolic HTN, 66-67
- Electroencephalogram (EEG), arousal of, in OSA, 73
- EMC (essential mixed cryoglobulinemia), *see* Mixed cryoglobulinemia
- Emergencies in DAC, crash cart for, 239
- Emtricitabine, 385
- ENaC (epithelial sodium channel)-related genes in HTN, 117-118
- Endothelin-1 (ET-1),  
in essential HTN, 7  
in HRS, 294-295
- Endotheliosis, glomerular, described, 60
- Endothelium in HTN  
in essential HTN, 5-8  
in preeclampsia, 59  
in renal failure-associated HTN, 22-23
- Endothelium-related factors in HTN, 118-119

- Endotoxin in HRS, 295
- End-stage renal disease (chronic renal failure), *see* Chronic kidney disease; Prostaglandin D<sub>2</sub> synthase, progression of chronic renal failure and; Renal failure-associated hypertension
- Energy dissipation genes in obesity, 102
- Entecavir, 385
- Epidemiology
- of CVD in early stages of CKD, 494-495
  - see also* Epidemiology, genetic; Epidemiology of HBV infection; Epidemiology of HCV infection; Incidence; Prevalence and specific conditions
- Epidemiology, genetic
- of HTN, 27
  - of stroke, 127
- Epidemiology of HBV infection
- of chronic HBV infection in candidates to RTX and RTX recipients, 375
  - in HD patients, 343-344
  - in PD and HD patients, compared, 351-353
- Epidemiology of HCV infection
- in HD patients, 331-332
  - and in PD and HD patients, compared, 351-353
- Epithelial sodium channel (ENaC)-related genes in HTN, 117-118
- Equipment
- percutaneous bone biopsy, 272
  - renal and urinary tract ultrasound, 244-246
- Erythropoietin therapy, *see* Anemia, rHuEPO therapy of
- ESRD (end-stage renal disease; chronic renal failure), *see* Chronic kidney disease; Prostaglandin D<sub>2</sub> synthase, progression of chronic renal failure and; Renal failure-associated hypertension
- Essential (primary) hypertension (HTN), genetics of, 135-147
- candidate gene for HTN, 145
  - clone contig creation in, 144-145
  - cosegregation analysis in, 137-138
  - QTL mapping in, *see* Quantitative trait loci mapping in essential hypertension
- Essential (primary) hypertension (HTN), pathophysiology of, 3-16
- endothelium in, 5-8
  - heart in, 3-5
  - perspectives on, 13
  - role of kidneys in, 12-13
  - vascular smooth muscle contractions and, *see* Vascular smooth muscle contractions in essential HTN
- Essential hypertension, *see* Essential hypertension, genetics of; Essential hypertension, pathophysiology of
- Essential mixed cryoglobulinemia, *see* Mixed cryoglobulinemia
- Establishing a DAC, conditions necessary for, 237
- Estrogen
- effects of, in stroke, 131-132
  - PAI-1 regulation by, 401
- Estrogen (hormone) replacement therapy, 69, 501
- ET-1, *see* Endothelin-1
- Etiology
- of anemia in CRI, 474
  - of iron-deficiency anemia in CKD, 479-480
  - see also* specific conditions
- Evaluation
- of bone biopsy specimens, 274
  - of DAC, 239-241
  - of laboratory measurements for CKD in K/DOQI guidelines, 451-453
  - of living kidney donors, 380, 521-522
  - patient, *see* Patient evaluation
  - PRB tissue, 260-261
  - vascular access, prior to angioplasty, 205-206
  - see also* Diagnosis; Pre-renal transplant evaluation of RTX candidates with CKD
- Examination, physical, of vascular access, 183-185
- Excitotoxicity, effects of estrogens on, stroke and, 132
- Exercise, HTN prevention with, 38, 68
- Exteriorization of chronic PD catheters, 232-233
- Extra-adrenal pheochromocytoma, described, 89
- Extracellular matrix (ECM), fibrinolytic system regulating formation of, 399
- Extrahepatic complications of HCV infection in HD patients, 333
- Extravasation, venous, in vein rupture, 208-209
- Facility credentials and privileges based on interventional nephrology training, 278-280
- Factor X, role of circulating, in preeclampsia, 59
- Familial paraganglioma (PGL), 94-95
- Fatty acids, insulin resistance and increased levels of, in syndrome X, defective *Cd36* in, 150-152
- FCH, *see* Fibrosing cholestatic hepatitis
- Fentanyl, 214
- Ferric gluconate supplementation, IV sodium, 481, 482, 484, 485
- Ferrous sulfate supplementation, IV, 481
- Fibrinolysis, *see* Renin-angiotensin aldosterone system, fibrinolysis and, in progressive renal disease
- Fibrinolytic system, ECM formation regulated by, 399
- Fibrosing cholestatic hepatitis (FCH)
- post-RTX, and HBV infection, 378
  - and RTX for HCV infection and, 367
- Fibrosis, 399-401
- effects of RAAS interruption on, 401
  - PAI-1 promoting, 399-400
- Financial implications, *see* Cost of interventional nephrology procedures
- Fistulae, *see* Arteriovenous fistulae
- Focal segmental glomerulosclerosis (FSGS), post-RTX recurrence of, 519
- Folate supplementation, 468, 469, 499
- Free iron release, IV iron preparations and, 483-484
- Free radicals, IV iron preparations and generation of, 484
- Frequency of rHuEPO dosing for anemia of CRI, 475-476
- FSGS (focal segmental glomerulosclerosis), post-RTX recurrence of, 519
- G proteins in HTN, 118
- Ganciclovir, 385
- Gender, as determinant of stroke, 129-132
- Gene(s)
- predisposing to pheochromocytoma in carriers of germline mutations, 95-96
  - see also* Gene expression; Statistical gene mapping of traits;



- Transgenesis and gene targeting *entries beginning with term: Genetic and specific genes*
- Gene expression
- inducible systems of, in additive transgenesis, 155-156
  - profiling of, for QTL characterization in essential HTN, 145-146
- Genetic disorder(s) of pheochromocytoma, 91-95
- familial PGL as, 94-95
  - MEN 2 as, 91-92, 95, 96
  - NF-1 disease as, 94, 96
  - VHL disease as, 92-96
- Genetic distances, translating, into physical distances in QTL mapping of essential HTN, 143
- Genetic markers in statistical gene mapping of traits
- complex traits, 110-111
  - monogenic traits, 106
- Genetics
- of preeclampsia, 56-57
  - see also* Epidemiology, genetic; Gene(s); Genetic disorder(s) of pheochromocytoma; Genetic distances; Genetics of HTN; Genome scan; Genome screens and specific genes
- Genetics of HTN, 27-34
- of AME-associated HTN, 28, 29, 82-84, 86
  - of diabetic nephropathy-associated HTN, 31-32
  - of essential HTN, *see* Essential hypertension, genetics of
  - genetic epidemiology of HTN, 27
  - of GRA-associated HTN, 28, 29, 81-82, 84, 86
  - HTN regulatory genes, 28
  - introduction to, 79-80
  - of Liddle's syndrome-associated HTN, 28, 29, 82, 84, 86
  - linkage studies for new blood pressure loci in, 120-123
  - see also* Apoptosis and proliferation in HTN; *Cd36* in syndrome X; Essential hypertension, genetics of; Hypertension, as complex trait; Monogenic hypertension; Mutations; Obesity, genetics of; Renal and cardiovascular physiology; Statistical gene mapping of traits; Stroke, genetics of; Transgenesis and gene targeting
- Genome scan, total, in apoptosis and proliferation, 165-167
- Genome screens in obesity, 102
- Germline mutations, genes predisposing to pheochromocytoma in carriers of, 95-96
- GFR, *see* Glomerular filtration rate
- Gitelman's syndrome, 29
- Glomerular endotheliosis, described, 60
- Glomerular filtration rate (GFR)
- in renal failure-associated HTN, 17-18
  - see also* Glomerular filtration rate in CKD
- Glomerular filtration rate (GFR) in CKD
- level of, associated with CKD complications, 453
  - in U.S. CKD patients, 443
- Glomerular pathology
- in cirrhosis, 302-304
  - see also* specific conditions
- Glomerulonephritis (GN) in liver disease, 302-308
- in AAT deficiency, 306-307
  - and glomerular pathology in cirrhosis, 302-304
  - in HBV infection, 305-306
  - in HCV infection, 304-305
  - see also* Cryoglobulinemia(s), kidney and liver involvement in; Cryoglobulinemic glomerulonephritis
- Glomerulosclerosis (GS)
- focal segmental, post-RTX recurrence of, 519
  - hepatic, in GN, 302-303, 306
- Glucocorticoid(s), 29
- see also* Glucocorticoid-remediable aldosteronism, HTN in; Glucocorticoid resistance
- Glucocorticoid-remediable aldosteronism (GRA), HTN in
- HTN pathophysiology in, 46-48
  - monogenic HTN, 28, 29, 81-82, 84, 86
- Glucocorticoid resistance, HTN and, 46, 49
- Glucose
- GRA therapy with, 29
  - PAI-1 regulation by, 400-401
- Glyburide, 498
- GN, *see* Glomerulonephritis in liver disease
- Gordon's syndrome, 84
- GRA, *see* Glucocorticoid-remediable aldosteronism, HTN in
- Grades of venous extravasation in vein rupture, 208-209
- Gross hematuria, post-PRB, 263
- Growth hormone deficiency in OSA-related HTN, 75
- GS, *see* Glomerulosclerosis
- Guidelines
- on post-RTX monitoring of recipients with chronic HBV infection, 382
  - on pre-RTX management of chronic HBV infection, 380
  - see also* Clinical practice guidelines, K/DOQI CKD
- Guidewire selection for angioplasty of AVF and AVGs, 206
- HBV, *see* Hepatitis B virus infection
- HCC (hepatocellular carcinoma), post-RTX, and chronic HBV infection, 378, 382
- HCV, *see* entries beginning with term: Hepatitis C
- HD, *see* Hemodialysis
- Healthy living clinic, *see* Stabilization of CKD, role of comprehensive renal care clinic in
- Heart
- role of, in essential HTN, 3-5
  - see also* Heart failure and entries beginning with element: Card-
- Heart failure, congestive, BNP in, 427-429
- Hematoma, post-PRB perinephric, 263-264
- Hematuria, post-PRB microscopic and/or gross, 263
- Hemodialysis (HD)
- for cryoglobulinemic GN, 316
  - HD mode and renal failure-associated HTN, 23
  - intermittent, for HRS, 297, 298
  - vascular access for, *see* Vascular access
  - see also* Hepatitis B and/or C virus infection in PD and HD patients; Hepatitis B virus infection in HD patients; Hepatitis C virus infection in HD patients and entries beginning with terms: Dialysis access
- Hemodynamics
- acute OSA effects on, 72-73
  - changes in, in HRS, 293-294
  - hemodynamic criteria applied to balloon angioplasty outcome, 208
  - see also* Blood flow; Blood pressure
- Hemofiltration, continuous venovenous, for HRS, 297, 298
- Hemoglobin level
- post-PRB drop in, 263
  - rHuEPO therapy initiation for anemia of CRI and, 475-476



- Hemostasis in angioplasty of AVF and AVGs, 209
- Heparin, 206, 207, 216, 218
- Hepatic glomerulosclerosis in GN, 302-303, 306
- Hepatic IgA (immunoglobulin A) nephropathy (Berger's disease) in GN, 302
- Hepatitis B and/or C virus (HBV and/or HCV) infection in PD and HD patients
- prevalence of, compared, 351-353
  - risk factors for, compared, 353-355
- Hepatitis B and/or C virus (HBV and/or HCV) infection in PD patients, 351-360
- conclusion on, and practical implications of, 358-359
  - diagnosis of, 356
  - outcome of, 356-357
  - prevention and therapy of, 357-358
  - routes of transmission of HCV infection in, 355-356
  - see also* Hepatitis B and/or C virus infection in PD and HD patients
- Hepatitis B virus (HBV) infection
- in GN, 305-306
  - pre-existing, pre-RTX evaluation of, in CKD patients, 518
  - see also* Chronic hepatitis B virus infection, RTX and; Hepatitis B and/or C virus infection in PD patients; Hepatitis B virus infection in HD patients
- Hepatitis B virus (HBV) infection in HD patients, 340-350
- characteristics of, 340-341
  - epidemiology of, 343-344
  - and immunopathology in HD patients, 341-342
  - prognosis of, 342-343
  - therapy of, *see* Therapy and management of HBV infection in HD patients
  - vaccination against, 344-347
- Hepatitis C virus (HCV) infection
- pre-RTX evaluation of pre-existing, in RTX candidates with CKD, 518
  - see also* Hepatitis B and/or C virus infection in PD patients; Hepatitis C virus infection, cryoglobulinemia and; Hepatitis C virus infection, RTX and
- Hepatitis C virus (HCV) infection, cryoglobulinemia and, 309, 310
- in cryoglobulinemic GN, 304-305
  - preventive therapy of HCV infection and therapy of cryoglobulinemia, 314-316
  - type II cryoglobulinemia, 304
- Hepatitis C virus (HCV) infection, RTX and, 333-336, 365-374
- fibrosing cholestatic hepatitis and, 367
- HCV-infected HD patients compared with RTX recipients, 333-334
- for HCV infection-induced renal disease, 367-368
  - HD patients on waiting list for RTX and, 361-364
  - infection impact on patient and allograft survival, 369
  - pathology of, 366
  - post-RTX clinical course and, 366
  - post-RTX infections and rejection and, 368-369
  - role of immunosuppression in, 369-370
  - therapy of, 334-336
  - use of anti-HCV-positive kidney donors and, 370-372
- Hepatitis C virus (HCV) infection in HD patients, 331-339
- epidemiology of, 331-332
  - natural history and extrahepatic complications of, 333
  - recommendations on, 336
  - therapy of, 334-336
  - virology of, 332-333
  - on waiting list for RTX, 361-364
- Hepatocellular carcinoma (HCC), post-RTX, and chronic HBV infection, 378, 382
- Hepatorenal syndrome (HRS), 290-301
- acute tubular necrosis with, 295-296
  - ascites in, *see* Ascites in HRS
  - defined, 290-291
  - incidence and prognosis of, 291
  - liver cirrhosis in, *see* Liver cirrhosis in HRS
  - Na retention in, 292
  - renal and hemodynamic changes in, 293-294
  - renal pathology in, 295
  - therapy and management of, *see* Therapy and management of HRS
- History of K/DOQI, 449-450
- HIV (human immunodeficiency virus) infection, pre-existing, in CKD patients, pre-RTX evaluation of, 518
- HLA (human leukocyte antigen) phenotypes, pre-renal transplant serum screening for antibodies to, in RTX candidates with CKD, 520
- HLA (human leukocyte antigen) typing, pre-RTX, in RTX candidates with CKD, 519-520
- HMG-CoA (3-hydroxy-3-methylgluturate-coenzyme A) reductase inhibitors (statins), 469, 500-502
- Homeostasis, BNP and cardiovascular, 426-429
- renal, 430-431
- Hormone (estrogen) replacement therapy, 69, 501
- Hospital credentials and privileges based on interventional nephrology training, 278-280
- HRS, *see* Hepatorenal syndrome
- 11 $\beta$  (beta) HSD-(hydroxysteroid dehydrogenase)-associated hypertension (HTN), 46, 117-118
- HTN, *see* Hypertension
- Human erythropoietin, *see* Anemia, rHuEPO therapy of
- Human immunodeficiency virus (HIV) infection, pre-existing, pre-RTX evaluation of, in RTX candidates with CKD, 518
- Human leukocyte antigen, *see* HLA phenotype; HLA typing
- Hybrid analysis of statistical gene mapping, 106, 108
- Hydrochlorothiazide, 403
- 11 $\beta$  (beta)-Hydroxylase deficiency-associated hypertension (HTN), 46, 48
- 17 $\beta$  (beta)-Hydroxylase deficiency-associated hypertension (HTN), 46, 48
- 3-Hydroxy-3-methylgluturate-coenzyme A (HMG-CoA) reductase inhibitors (statins), 469
- 11 $\beta$  (beta)-Hydroxysteroid dehydrogenase (HSD)-associated hypertension (HTN), 46, 117-118
- Hyperaldosteronism, primary, HTN associated with, 45-47
- Hypercalcemia, role of, in renal failure-associated HTN, 21-23
- Hyperglycemia, as risk factor for CVD in CKD, 498-499
- Hyperhomocysteinemia, as risk factor for CVD in CKD, 468, 469, 499-500
- Hyperlipidemia, as risk factor for CVD in CKD, 468, 469, 500
- Hyperparathyroidism, as risk factor for CVD in CKD, 467-468
- Hypertension (HTN)
- BNP in, 429-430
  - as risk factor for CVD with CKD, 466-467, 497-498

- see also* Genetics of HTN; Hypertension, as complex trait;  
Hypertension, pathophysiology of  
Hypertension (HTN), as complex trait, 115-126  
   $\alpha$ - and  $\beta$ -adrenergic receptor role in sympathetic tone and, 119-120  
  ANP in, 120  
  association studies of, 116  
  ENaC-related genes and adducin genes and, 117-118  
  endothelium-related factors in, 118-119  
  G proteins in, 118  
  11 $\beta$ -hydroxysteroid dehydrogenase gene in, 46, 117-118  
  linkage studies for new blood pressure loci in, 120-123  
  renin-angiotensin system genes in, 116-117  
Hypertension (HTN), pathophysiology of  
  introduction to, 1-2  
  *see also* Adrenal hypertension; Diet and lifestyle modification, HTN prevention and management with; Elderly, the, HTN in; Essential hypertension, pathophysiology of; Obstructive sleep apnea-related hypertension; Preeclampsia; Renal failure-associated hypertension  
Hypertension metabolic syndrome, *see* Cd36 in syndrome X  
Hypoxemia in OSA, 73
- Idiopathic hyperaldosteronism (IHA), HTN in, 46-47  
IFN- $\alpha$ , *see* Interferon- $\alpha$   
IgA (immunoglobulin A) nephropathy (Berger's disease)  
  hepatic, in GN, 302  
  post-RTX recurrence of, 519  
IHA (idiopathic hyperaldosteronism), HTN in, 46-47  
IL-2 (interleukin-2) in HBV infection, 346  
Imaging, *see* Computed tomography and entries beginning with term; Ultrasound  
Immune dysfunction in preeclampsia, 55-56  
Immunization against HBV infection, 344-347, 358, 383  
Immunoglobulin A, *see* IgA nephropathy  
Immunologic evaluation, pre-RTX, of RTX candidates with CKD, 519-521  
Immunopathology of HBV infection in HD patients, 341-342  
Immunosuppression in RTX  
  for chronic HBV-infected patients, 381  
  for HCV-infected patients, 369-370  
  *see also* specific immunosuppressants  
Implantation, defective placental, preeclampsia and, 54-55  
Incidence  
  of chronic PD catheter complications, placement method and, 227  
  of HRS, 291  
  *see also* Prevalence and specific conditions  
Indications  
  for percutaneous bone biopsy, 272  
  for PRB, 254-255  
  for pre-RTX surgical procedures in CKD patients, 517  
  for renal and urinary tract ultrasound, 242-244  
  *see also* specific conditions  
Inducible gene expression systems in additive transgenesis, 155-156  
Infarction  
  leukoencephalopathy with subcortical, cerebral autosomal-dominant arteriopathy with, 128  
  myocardial, BNP in, 429
- Infections  
  dialysis access, in CKD patients, 511-512  
  IV iron-associated, 485  
  post-RTX, impact of HCV infection on, 368-369  
  pre-existing, pre-RTX evaluation of, in RTX candidates with CKD, 518  
  *see also* Infections with GN and specific infections  
Infections with GN, 304-306  
  HBV, 305-306  
  HCV, 304-305  
Inflammation, as risk factor for CVD in CKD, 468, 469, 501-502  
Initiation of rHuEPO therapy for anemia of CRI, hemoglobin level and, 475-476  
Insertion of cuffed, tunneled catheters  
  complications of, 213-214  
  imaging techniques used in, 212-213  
  site selection for, 211-212  
  techniques of, 214-216  
Insulin, PAI-1 regulation by, 400-401  
Insulin resistance, increased fatty acid levels and, in syndrome X, defective Cd36 in, 150-152  
Insulin therapy, 498  
Interferon- $\alpha$  (IFN- $\alpha$ )  
  for HBV infection, 347-348, 358, 382, 383  
  for HCV infection, 304-306, 314-316, 334-336, 358, 359, 367, 368, 370  
  pegylated, 305, 314  
Interleukin-2 (IL-2) in HBV infection, 346  
Intermittent hemodialysis (HD) for HRS, 297, 298  
Intermittent peritoneal dialysis (IPD), HBV and/or HCV infection in patients on, 352, 357  
Interpretation, ultrasound image  
  of color flow Doppler ultrasound, 200  
  of renal and urinary tract, 248-251  
Intervention, *see* Therapy and management  
Interventional nephrology, *see* Diagnostic and interventional nephrology  
Interventional studies in pre-RTX evaluation of RTX candidates with CKD, 516-517  
Intrahepatic portosystemic shunt, transjugular, for HRS, 297  
Intravenous (IV) ferrous sulfate supplementation, 481  
Intravenous (IV) iron dextran supplementation, 479, 481-483  
Intravenous (IV) iron sucrose supplementation, 481-484  
Intravenous (IV) sodium ferric gluconate supplementation, 481, 482, 484, 485  
4'-Iodo-4'-deoxy-doxorubicin (doxorubicin), 326  
IPD (intermittent peritoneal dialysis), HBV and/or HCV infection in patients on, 352, 357  
  Iron-deficiency anemia in CKD, 479-487  
  approach to management of, 480-482  
  benefits of iron replacement in, 480  
  diagnosis of, 480  
  etiology of, 479-480  
  risks of correction of, 482-485  
Iron dextran supplementation, IV, 479, 481-483  
Iron sucrose supplementation, IV, 481-484  
Ischemia, placental, in preeclampsia, 57  
Isolated systolic hypertension (HTN) in the elderly, 67-68  
Isorbide mononitrate, 68, 69  
IV, *see* entries beginning with term; Intravenous

- Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNCVI) guidelines, 35, 41
- K (potassium) supplementation, HTN prevention and management with, 37
- Kappa ( $\kappa$ )-opioid antagonists, 297
- K/DOQI (Kidney/Disease Outcomes Quality Initiative), *see* Clinical practice guidelines, K/DOQI CKD
- Kidney/Disease Outcomes Quality Initiative, *see* Clinical practice guidelines, K/DOQI CKD
- Kidneys  
   role of, in essential HTN, 12-13  
   *see also* Ultrasound of kidney and urinary tract entries beginning with term: Renal element: Nephro- and specific conditions
- Kinase, rho-, in vascular smooth muscle contractions, essential HTN and, 10
- Kinase C, role of protein, in vascular smooth muscle contractions, essential HTN and, 9-10
- Knockin strategies, 158-159
- Knockout strategies, 157
- Knowledge, skills, and competence in interventional nephrology procedures  
   in chronic PD catheter placement, 235  
   in color flow Doppler ultrasound of AVF and AVGs, 200  
   in PRBs, 264-265  
   training and, 278; *see also* Training in interventional nephrology
- Laboratory measurements  
   in CKD, K/DOQI guidelines on evaluation of, 451-453  
   *see also* specific conditions
- Lamivudine, 306, 347-348, 382-384, 518
- Late arteriovenous fistula (AVF) failure, angioplasty for, 202-203
- LC (light-chain) disorders, *see* Amyloid light-chain amyloidosis; Light chain deposition disease
- LCDD, *see* Light-chain deposition disease
- Learning approach to gene mapping of complex traits, 111
- Leukoencephalopathy, cerebral autosomal-dominant arteriopathy with subcortical infarcts and, 128
- Licorice and carbenoxolone ingestion, HTN due to, 45, 46
- Liddle's syndrome (pseudaldosteronism)-associated hypertension (HTN)  
   as monogenic HTN, 28, 29, 82, 84, 86  
   pathophysiology of, 46, 49-50
- Lidocaine, 207
- Lifestyle, *see* Diet and lifestyle, HTN and
- Light-chain deposition disease (LCDD), 319-327  
   liver involvement in, 325  
   renal involvement in, 322-325  
   therapy of, 325-327
- Light-chain disorders, *see* Amyloid light-chain amyloidosis; Light chain deposition disease
- Limitations of K/DOQI CKD guidelines, 455-456
- Linkage analysis of statistical gene mapping, 105, 106  
   for new blood pressure loci, 120-123
- Linkage disequilibrium gene mapping, 106, 108-109
- Lipoprotein(a) [Lp(a)], as risk factor for CVD in CKD, 468, 501
- Liver cirrhosis  
   as contraindication to RTX, 334  
   in GN, glomerular pathology in, 302-304  
   in HBV infection, *see* Liver cirrhosis in HBV infection  
   in HRS, *see* Liver cirrhosis in HRS
- Liver cirrhosis in HBV infection  
   post-RTX development of, in chronic infection, 377-380  
   prognosis and, 343
- Liver cirrhosis in HRS, 293-296  
   and acute tubular necrosis, 296  
   and HRS prognosis, 291  
   neuroendocrine response to vasodilation in, 294-295  
   renal and hemodynamic changes and, 293, 294  
   role of endotoxin in, 295
- Liver diseases, kidney and  
   introduction to, 287-289  
   *see also* Amyloid light-chain amyloidosis; Cryoglobulinemia(s), kidney and liver involvement in; Glomerulonephritis in liver disease; Hepatitis B virus infection; Hepatitis C virus infection; Hepatorenal syndrome; Light-chain deposition disease
- Liver transplantation, HRS management with, 298
- Living kidney donors, 521-523  
   anti-HCV positive, 370-372  
   evaluation of, 380, 521-522  
   short- and long-term risks to, 523
- Lobucavir, 385
- Loci, *see* Blood pressure loci; Quantitative trait loci mapping in essential HTN
- Long-term risks of kidney donation, 523
- Loop diuretics, *see* specific diuretics
- Lp(a) [lipoprotein(a)], as risk factor for CVD in CKD, 468, 501
- LPA, *see* Lysophosphatidic acid in mesangial cell proliferation and apoptosis
- Lysophosphatidic acid (LPA; 1-acyl-sn-glycerol-3-phosphate)  
   in mesangial cell proliferation and apoptosis, 415-422  
   and bimodal effects of PDGF on mesangial cell proliferation and apoptosis, 416-417  
   and LPA as determinant of mesangial growth, 420-421  
   LPA effects of mesangial cell survival and proliferation, 417-418  
   and LPA signal transduction, 418-419  
   other mesangial cell responses to LPA, 419-420
- Magnesium (Mg) supplementation, HTN prevention and management with, 40
- Malignancies, pre-existing, pre-RTX evaluation of RTX candidates with CKD, 517-518
- Malignant pheochromocytoma, 96
- Malnutrition, protein-energy, as risk factor for CVD in CKD, 468, 469
- Management, *see* Therapy and management
- MAP (mitogen-activated protein) kinase, role of, in vascular smooth muscle contractions, essential HTN and, 10
- Mapping, *see* Quantitative trait loci mapping of defective *Cd36* in syndrome X; Quantitative trait loci mapping in essential HTN; Statistical gene mapping of traits
- MARS (Molecular Adsorbent Recirculating System) for HRS, 298
- Maturation of dialysis access, 509-510
- MC, *see* Mixed cryoglobulinemia

- Medical director of DAC, 238
- Medical management, *see* Therapy and management and specific pharmaceutical agents
- Melphalan, 325, 326
- Membranoproliferative glomerulonephritis (MPGN), cryoglobulinemia and, 311, 315, 316
- Membranoproliferative glomerulonephritis (MPGN) type I and II, post-RTX recurrence of, 519
- Membranous nephropathy  
HBV infection and, 305  
post-RTX recurrence of, 519
- MEN 2 (multiple endocrine neoplasia type 2), 91-92, 95, 96
- Mendelian inheritance, *see* entries beginning with term: Monogenic
- Mesangial cell proliferation and apoptosis, *see* Lysophosphatidic acid in mesangial proliferation and apoptosis
- Mesangial growth, LPA and, 420-421
- Metabolic control analysis, described, 124
- Metabolic syndrome, *see* Cd36 in syndrome X
- Metformin, 498
- Methylprednisolone, 314, 381
- Mg (magnesium) supplementation, HTN prevention and management with, 40
- Microalbuminuria in U.S. CKD patients, 443
- Microsatellites (short tandem repeats), defined, 106
- Microscopic hematuria, post-PRB, 263
- Midazolam, 214
- Midodrine, 297
- Mineralocorticoid hypertension (HTN)  
characteristics of, 45  
types of, 46; *see also* specific forms of mineralocorticoid hypertension; for example: Aldosterone-producing adenoma; Glucocorticoid-remediable aldosteronism, HTN in
- Mineralocorticoid receptor hypertension (MR HTN), 83-84, 86
- Misoprostol, 298
- Mitogen-activated protein (MAP) kinase C, role of, in vascular smooth muscle contractions, essential HTN and, 10
- Mixed cryoglobulinemia (MC), 309-313  
definition and classification of, 309, 310  
liver involvement in, 313-314  
renal involvement in, 310-313
- MLC (myosin light chain), role of Ca<sup>2+</sup>-dependent phosphorylation of, in vascular smooth muscle contractions, essential HTN and, 8-9
- MMF (mycophenolate mofetil), 370, 381
- Model-based (parametric) analysis of statistical gene mapping, 106-107, 109-110
- Model-free (nonparametric) analysis of statistical gene mapping, 106-109
- Molecular Adsorbent Recirculating System (MARS) for HRS, 298
- Monitoring  
post-RTX, of chronic HBV infection recipients, 382  
of rHuEPO therapy for anemia of CRI, 476  
*see also* Monitoring of vascular access; Patient observation
- Monitoring of vascular access  
of chronic PD catheter placement by certified physicians, 235  
with color flow Doppler ultrasound, 190-191, 195-196  
of vascular access Q<sub>a</sub>, 190-191
- Monoclonal light chain disorders, *see* Amyloid light-chain amyloidosis; Light-chain deposition disease
- Monogenic (Mendelian) forms  
of HTN, *see* Monogenic hypertension  
of obesity, 100-102  
of stroke, 127-128
- Monogenic (Mendelian) hypertension (HTN), 81-88  
in AME, 28, 29, 82-84, 86  
in autosomal-dominant HTN with brachydactyly, 84-87  
in GRA, 28, 29, 81-82, 84, 86  
in Liddle's syndrome, 28, 29, 81-82, 84, 86  
in mineralocorticoid receptor HTN, 83-84, 86  
in PHA type II, 84  
*see also* Pheochromocytoma
- Monogenic traits, statistical gene mapping of, 105-106  
analysis approaches used in, 105-106  
with genetic markers, 106  
by recombination, 105  
starting points in, 105
- Morbidity, CKD-associated  
pre-existing, *see* Pre-renal transplant evaluation of pre-existing morbidities in RTX candidates with CKD  
in U.S., resource utilization and, 444-445  
*see also* specific conditions
- Morphologic features of cryoglobulinemic GN, 311
- Mortality  
CKD, in U.S., 445-446  
RTX recipient, influence of chronic HBV infection on, 376-378
- MPGN (membranoproliferative glomerulonephritis), cryoglobulinemia and, 311, 315, 316
- MPGN (membranoproliferative glomerulonephritis) type I and II, post-RTX recurrence of, 519
- MR HTN (mineralocorticoid receptor hypertension), monogenic character of, 83-84, 86
- Multiple endocrine neoplasia type 2 (MEN 2), 91-92, 95, 96
- Mutations  
germline, genes predisposing to pheochromocytoma in carriers of, 95-96; *see also* Genetic disorder(s) of pheochromocytoma  
relevance of HBV, to RTX recipients with chronic HBV infection, 380-381  
*see also* Genetics of HTN and specific conditions
- Mycophenolate mofetil (MMF), 305, 370, 381
- Myocardial infarction, BNP in, 429
- Myosin light chain (MLC), role of Ca<sup>2+</sup>-dependent phosphorylation of, in vascular smooth muscle contractions, essential HTN and, 8-9
- Na, *see* entries beginning with term: Sodium
- Natriuresis-diuresis-pressure, measurements of, 175-176
- Natriuretic peptide, *see* Atrial natriuretic peptide; Brain natriuretic peptide, role of; C-type natriuretic peptide; Natriuretic peptide receptors
- Natriuretic peptide receptors, function of, 426
- Natural history of HCV infection in HD patients, 333
- Naturally occurring cardiovascular and renal mediators  
introduction to, 391-392  
*see also* Brain natriuretic peptide, role of; Lysophosphatidic acid in mesangial cell proliferation and apoptosis; Nephron in renal disease; Prostaglandin D<sub>2</sub> synthase, progression of chronic renal failure and; Renin-angiotensin aldosterone system, fibrinolysis and, in progressive renal disease

- Necrosis, acute tubular, with HRS, 295-296
- Needles  
for angioplasty of AVF and AVGs, 206  
PRB, 259, 260
- Nephrin in renal disease, 393-398  
in diabetic nephropathy, 395  
identification of, 393  
new directions in biology of, 396  
and other podocyte-specific proteins, 396  
in proteinuric renal disease, 394  
and slit diaphragm, 393-394
- Neurofibromatosis-1 (NF-1) disease, 94, 96
- New techniques for placement of chronic PD catheters, 229
- NF-1 (neurofibromatosis-1) disease, 94, 96
- Niacin, 501
- Nifedipine, 21
- Niravoline, 297
- Nitric oxide (NO), role of, in essential HTN, 6-8
- Noisy approach to gene mapping of complex traits, 110
- Nondippers, 17, 72
- Nonepithelial action of corticosteroids, adrenal HTN and, 44-45
- Nonparametric (model-based) analysis of statistical gene mapping, 106-109
- Nonsteroidal anti-inflammatory drugs (NSAIDs), 261, 292, 412, 413
- Northwestern Clinic, *see* Stabilization of CKD, role of comprehensive renal care clinic in
- NSAIDs (nonsteroidal anti-inflammatory drugs), 261, 292, 412, 413
- Nutrition  
and protein-energy malnutrition as risk factor for CVD in CKD, 468, 469  
*see also* Diet and lifestyle, HTN and; Nutritional support
- Nutritional support  
of CKD patients, disease stabilization and, 528-529  
*see also* Supplementation
- Obesity, genetics of, 100-104  
energy dissipation genes in, 102  
genetics of HTN related to, 102-103  
genome screens in, 102  
models of, 101, 102  
monogenic and polygenic forms of obesity, 100-102
- Obesity, HTN and, 27, 30  
dietary Ca supplementation effects on, 39  
in the elderly, 68  
genetics related to genetics of, 102-103; *see also* Obesity, genetics of  
in OSA-related HTN, 74-75  
prevention of, *see* Diet and lifestyle modification, HTN prevention and management with  
renal failure-associated HTN, 23
- Observation, post-PRB patient, 260-262
- Obstruction, upper airway, with ongoing respiratory effort in OSA, 72-73
- Obstructive sleep apnea (OSA)-related hypertension (HTN), 71-77  
and acute hemodynamic consequences of OSA, 72-73  
effects of OSA treatment on HTN, 71-72  
growth hormone deficiency in, 75  
increased sympathomimetic activity in, 73-74  
obesity and, 74-75  
prevalence of, 71  
snoring and, 71
- Octapressin, 296
- OFRs (oxygen-free radicals), role of, in renal failure-associated HTN, 23
- OKT3, 370
- Ongoing respiratory effort, upper airway obstruction with, in OSA, 72-73
- Operations manual of DAC, 238-241
- Organ perfusion in preeclampsia, 59-60
- Ornipressin, 296
- OSA, *see* Obstructive sleep apnea-related hypertension
- Osteodystrophy, *see* Percutaneous bone biopsy in ROS; Renal osteodystrophy in CKD
- Outcome  
of HBV and/or HCV infection in PD patients, 356-357  
*see also* Mortality; Outcome of interventional nephrology procedures; Prognosis; Survival and specific conditions
- Outcome of interventional nephrology procedures  
of angioplasty, 208  
of cuffed, tunneled catheter placement, 217  
in DAC, 239-241  
*see also* Successful outcome of interventional nephrology procedures
- Overflow hypothesis of Na retention, 292
- Oxidative stress  
in preeclampsia, 57-58  
as risk factor for CVD in CKD, 468, 469
- Oxygen-free radicals (OFRs), role of, in renal failure-associated HTN, 23
- PA (primary hyperaldosteronism)-associated hypertension (HTN), 45-47
- PAI-1, *see* Plasminogen activator inhibitor-1, fibrinolysis and, in progressive renal disease
- Paradoxical hypertension (HTN), defined, 19
- Paraganglioma (PGL)  
described, 89  
familial, 94-95
- Parametric (model-based) analysis of statistical gene mapping, 106-107, 109-110
- Parathyroid hormone (PTH), and hypercalcemia in renal failure-associated HTN, 21-22
- Pathology, pathogenesis, and pathophysiology  
of cryoglobulinemic GN, 312-313  
glomerular, in cirrhosis, 302-304  
of GN in HBV infection, 305-306  
of HCV infection, 366  
of ROS in CKD, 488-489  
*see also* Hypertension, pathophysiology of and specific conditions
- Patient evaluation  
of CKD patient for access placement, 508  
pre-angioplasty, of AVF and AVGs, 205-206  
pre-PRB, 256-257  
*see also* Pre-renal transplant evaluation of RTX candidates with CKD
- Patient observation, post-PRB, 260-262
- Patient preparation  
of CKD patient for RTX, 529

- for PRB, 259-260
- Patient survival
  - of dialyzed CKD patient, effects of CVD during predialysis period on, 461
  - with RTX, HCV infection impact on, 369
  - see also specific conditions*
- PD (peritoneal dialysis), *see* Chronic peritoneal dialysis catheters; Continuous ambulatory peritoneal dialysis; Hepatitis B and/or C virus infection in PD patients
- PDGF (platelet-derived growth factor), bimodal effects of, on mesangial cell proliferation and apoptosis, 416-417; *see also* Lysophosphatidic acid in mesangial cell proliferation and apoptosis
- Pegylated interferon- $\alpha$  (IFN- $\alpha$ ), 305, 314, 363
- Peptide, *see* Atrial natriuretic peptide; Brain natriuretic peptide, role of
- Percutaneous bone biopsy in ROS, 268-275
  - complications of, 274
  - equipment for, 272
  - indications for, 272
  - the procedure, described, 272-274
  - specimen evaluation in, 274
- Percutaneous renal biopsy (PRB), 254-267
  - complications of, 258, 260-264
  - contraindications to, 255-256
  - with CT, 259
  - indications for, 254-255
  - needles for, 259, 260
  - patient evaluation prior to, 256-257
  - patient preparation for, and procedure performance, 259-260
  - post-PRB patient observation, 260-262
  - skills and proficiency needed for, 264-265
  - specimen processing and evaluation of, 260-261
  - successful, 262
  - with ultrasound, 257-258
- Percutaneous transluminal angioplasty, *see* Angioplasty for AVF and AVGs
- Percutaneous vascular interventions
  - training for, 281-282
  - see also* Vascular access
- Perfusion of organs in preeclampsia, 59-60
- Perinephric hematoma, post-PRB, 263-264
- Peripheral arterial vasodilation hypothesis of Na retention, 292-293
- Peritoneal dialysis, *see* Chronic peritoneal dialysis catheters; Continuous ambulatory peritoneal dialysis; Hepatitis B and/or C virus infection in PD patients
- Peritoneoscopic placement of chronic PD catheter, 225
- Peroxisome proliferator-activated receptor- $\gamma$  (PPAR $\gamma$ ), PAI-1 regulation by, 400-401
- PGD<sub>2</sub>S, *see* Prostaglandin D<sub>2</sub> synthase, progression of chronic renal failure and
- PGL, *see* Paraganglioma
- PHA (pseudohypaldosteronism) type II, 84
- Pharmacy, satellite, in DAC, 239
- Phenotypes
  - of exaggerated proliferation in HTN, 161-162
  - HLA, pre-RTX serum screening for antibodies to, in RTX candidates with CKD, 520
- Pheochromocytoma, 89-99
  - diagnosis of, 89-91
  - genes predisposing to, in germline mutation carriers, 95-96
  - genetic disorders of, *see* Genetic disorder(s) of pheochromocytoma
  - malignant, 96
  - sporadic, 95
  - therapy of, 96
- Phosphate-calcium metabolism, abnormal, as risk factor for CVD in CKD, 467-468
- Phosphate restriction in ROS, 491
- Phosphorylation, role of Ca<sup>2+</sup>-dependent MLC, in vascular smooth muscle contraction, essential HTN and, 10
- Physical distances, translating genetic distances into, in QTL mapping of essential HTN, 143
- Physical examination for vascular access, 183-185
- Physical quantitative trait loci (QTL) mapping in essential HTN, 143-144
- Physiologic criteria applied to balloon angioplasty outcome, 208
- Physiology, *see* Renal and cardiovascular physiology
- PKC (protein kinase C), role of, in vascular smooth muscle contractions, essential HTN and, 9-10
- Placement, vascular access
  - of AVGs, 187
  - in CKD, patient evaluation for, 508
  - of cuffed, tunneled catheters, *see* Cuffed, tunneled catheters, placement of
  - preoperative physical examination for, 185
  - see also* Placement of AVF; Placement of chronic PD catheters
- Placement of AVF
  - planning for, 185-186
  - preoperative examination for, 185
- Placement of chronic PD catheters
  - certification for monitoring of, 235
  - site selection for, 223
  - see also* Placement of chronic PD catheters, techniques of
- Placement of chronic PD catheters, techniques of, 224-227
  - effects of, on success of PD catheters, 227
  - new techniques of, 229
- Placental implantation in preeclampsia, 54-55
- Placental ischemia in preeclampsia, 57
- Plan
  - clinical action, for CKD, 447
  - see also* Planning, dialysis access
- Planning, dialysis access
  - for AVF placement, 185-186
  - in CKD, 507-509
- Plasminogen activator inhibitor-1 (PAI-1), fibrinolysis and, in progressive renal disease, 399-403
  - effects of RAAS interruption on PAI-1, 401
  - estrogen regulation of, 401
  - fibrosis promoted by, 399-400
  - in humans, 402-403
  - RAAS, glucose, insulin, and PPAR- $\gamma$  regulation of, 400-401
- Platelet-derived growth factor (PDGF), bimodal effects of, on mesangial cell proliferation and apoptosis, 416-417; *see also* Lysophosphatidic acid in mesangial cell proliferation and apoptosis
- Podocyte-specific proteins, *see* Nephritin in renal disease
- Policy and procedures, DAC, 239
- Polyarteritis nodosa in HBV infection, 306

- Polygenic forms  
 of HTN, *see* Essential hypertension  
 of obesity, 100-102
- Polymorphism, gene, *see* Genetics of HTN
- Polytetrafluoroethylene grafts, *see* Arteriovenous grafts
- Portosystemic shunt, transjugular intrahepatic, for HRS, 297
- Ports, subcutaneous vascular, as alternatives to cuffed, tunneled catheters, 217-218
- Positional cloning, defined, 138
- Postpartum renal dysfunction in preeclampsia, management of, 60
- Post-percutaneous renal biopsy (PRB) arteriovenous fistulae (AVF), 264
- Post-percutaneous renal biopsy (PRB) gross and/or microscopic hematuria, 263
- Post-percutaneous renal biopsy (PRB) hematoma, perinephric, 263-264
- Post-percutaneous renal biopsy (PRB) patient observation, 260-262
- Post-renal transplantation (RTX) course of chronic HBV, 376
- Post-renal transplantation (RTX) development of liver cirrhosis, chronic HBV infection and, 377-380
- Post-renal transplantation (RTX) fibrosing cholestatic hepatitis (FCH) in HBV infection recipients, 378
- Post-renal transplantation (RTX) hepatocellular carcinoma (HCC) in chronic HBV infection recipients, 378, 382
- Post-renal transplantation (RTX) infections and rejection and, HCV infection and, 368-369
- Post-renal transplantation (RTX) monitoring of chronic HBV infection patients, 381-382
- Post-renal transplantation (RTX) recurrence of primary renal disease, 518-519
- Potassium (K) supplementation, HTN prevention and management with, 37
- PPAR- $\gamma$  (peroxisome proliferator-activated receptor- $\gamma$ ), PAI-I regulation by, 400-401
- Prazosin in HTN, 20
- PRB, *see* Percutaneous renal biopsy
- Predialysis period, CVD with CKD during, 461-462
- Predisposing genes to pheochromocytoma in carriers of germline mutations, 95-96
- Prednisolone, 381
- Prednisone, 316
- Preeclampsia, 54-64  
 cytokine formation in, 58-59  
 defective placental implantation in, 54-55  
 endothelial dysfunction in, 59  
 general hypotheses on, 54  
 genetics of, 56-57  
 immune dysfunction in, 55-56  
 oxidative stress in, 57-58  
 placental ischemia in, 57  
 postpartum renal dysfunction management and, 60  
 reduced organ perfusion in, 59-60  
 role of circulating factor X and syncytiotrophoblast in, 59
- Pre-existing morbidities, *see* Pre-renal transplantation evaluation of pre-existing morbidities in RTX candidates
- Pregnancy, *see* Preeclampsia
- Preoperative color flow Doppler ultrasound of vascular access, 198-199
- Preoperative physical examination of vascular access, 185
- Preparation, *see* Patient preparation
- Pre-renal transplantation (RTX) evaluation of pre-existing morbidities in RTX candidates  
 with chronic HBV infection, 379-380  
 with CKD, 517-518
- Pre-renal transplantation (RTX) evaluation of RTX candidates  
 with CKD, 515-525  
 data collection for, 516  
 immunologic, 519-521  
 interventional studies and pre-RTX surgery, 516-517  
 of pre-existing morbidities, 517-518  
 and risk of renal disease recurrence, 518-519
- Pre-renal transplantation (RTX) surgery in RTX candidates with CKD, 516-517
- Preselection of genetic markers in statistical gene mapping of complex traits, 111
- Pressure(s)  
 dilation, to be applied in angioplasty of AVF and AVGs, 206  
 diuresis-natriuresis-pressure measurements, 175-176  
 vascular access venous, 189-190  
*see also* Blood pressure
- Prevalence  
 of CKD in U.S., 442-444  
 of HBV and/or HCV infection in HD and PD patients, compared, 351-353  
 of obesity with HTN, 37  
 of OSA-related HTN, 71  
*see also* Incidence and specific conditions
- Prevention, *see* Diet and lifestyle modification, HTN prevention and management with; Prevention of HBV infection; Prevention of HCV infection
- Prevention of HBV infection  
 in PD patients, 357-358  
 with vaccination, 344-347, 358, 383
- Prevention of HCV infection  
 in cryoglobulinemia, 314-316  
 in PD patients, 357-358  
 in RTX recipients, 370
- Primary hyperaldosteronism (PA), HTN in, 45-47
- Primary hypertension, *see* Essential hypertension, genetics of; Essential hypertension, pathophysiology of
- Primary mixed cryoglobulinemia, *see* Essential mixed cryoglobulinemia
- Primary renal disease  
 post-RTX recurrence of, 519  
*see also* specific conditions
- Privileges and credentials, hospital and facility, based on interventional nephrology training, 278-280
- Procedural nephrology, *see* Diagnostic and interventional nephrology
- Procedures and policies, DAC, 239
- Proficiency, *see* Knowledge, skills, and competence in interventional nephrology procedures
- Prognosis  
 of ascites in HRS, 291  
 of HBV infection in HD patients, 342-343  
 of HRS, 291  
*see also* Outcome
- Programmed cell death, *see* Apoptosis and proliferation in HTN



- Progression  
 of chronic renal failure, *see* Prostaglandin D<sub>2</sub> synthase, progression of chronic renal failure and  
 of CKD, *see* Progression of CKD  
 of liver disease, chronic HBV-related, RTX and, 377-378
- Progression of CKD  
 and cardiovascular disease development, stratification of risk for, 453-454  
 comprehensive care and interim results in slowing, 530-531
- Progressive renal disease, *see* Renin-angiotensin aldosterone system, fibrinolysis and, in progressive renal disease
- Propranolol, 20
- Prostaglandin D<sub>2</sub> synthase (PGD<sub>2</sub>S), progression of chronic renal failure and, 407-414  
 and apoptosis, 409-410  
 background to, 414-415  
 clinical significance of, in chronic renal failure, 408-409  
 and dialysis dementia, 412-413  
 possible role of PGD<sub>2</sub>S in, 410-411  
 renal cyclooxygenase 2 and, 410-412
- Protein-energy malnutrition, as risk factor for CVD in CKD, 468, 469
- Protein kinase C (PKC), role of, in vascular smooth muscle contractions, essential HTN and, 9-10
- Proteinuria in CKD  
 microalbuminuria in U.S. CKD patients, 443  
 as risk factor for CVD, 495-497
- Proteinuric renal disease, nephrin in, 394; *see also* Nephrin in renal disease
- Protocol for color flow Doppler ultrasound of vascular access, 196-197
- Pseudoaldosteronism, *see* Liddle's syndrome-associated hypertension
- Pseudohypoaldosteronism (PHA) type II, monogenic HTN in, 84
- PTA (percutaneous transluminal angioplasty), *see* Angioplasty for AVF and AVGs
- PTFE (polytetrafluoroethylene) grafts, *see* Arteriovenous grafts
- PTH (parathyroid hormone), and hypercalcemia in renal failure-associated HTN, 21-22
- Puncture method, blind, of chronic PD catheter placement, 225-227
- Q<sub>a</sub>, *see* Blood flow
- QTL trait loci, *see* Quantitative trait loci mapping of defective *Cd36* in syndrome X; Quantitative trait loci mapping in essential HTN
- Quantitative trait loci (QTL) mapping of defective *Cd36* in syndrome X, 149-151  
*Cd36* established as QTL for insulin resistance and increased fatty acid levels, 150-151  
*Cd36* identified as candidate gene for hypertension metabolic syndrome, 149-150
- Quantitative trait loci (QTL) mapping in essential HTN, 137-146  
 gene identification strategies in, 145-146  
 physical mapping in, 143-144  
 RH mapping, 144  
 strategies for congenic breeding in context of, 139-140  
 in subcongenic lines, 141-143  
 translating genetic distances into physical distances in, 143
- RAAS, *see* Renin-angiotensin aldosterone system
- Racial disparities in U.S. CKD patients, 443-444
- Radiation hybrid (RH) quantitative trait loci (QTL) mapping in essential HTN, 144
- Rapamycin, 370
- Recirculation, vascular access, measurements of, 188-189
- Recombinant human erythropoietin, *see* Anemia, rHuEPO therapy of
- Recombination, statistical gene mapping of monogenic traits by, 105
- Recommendations  
 on HCV infection in HF patients, 336  
 for post-RTX monitoring of recipients with chronic HBV infection, 381-382  
 for pre-RTX management of chronic HBV patients, 380
- Recurrence of primary renal disease, post-RTX, 518-519
- Reference strains of congenic animals, 136
- Referral, early CKD patient, CKD stabilization and, 527
- Regulatory genes in HTN, 28
- Reimbursement  
 of rHuEPO therapy for anemia of CRI, 476  
*see also* Reimbursement of interventional nephrology procedures
- Reimbursement of interventional nephrology procedures, 282-284  
 of color flow Doppler ultrasound of vascular access, 199-200
- Rejection, renal allograft, impact of HCV infection on, 368-369
- Removal of chronic PD catheters, 233-235
- Renal actions of BNP, 430-431
- Renal allograft, *see* Allograft, renal
- Renal biopsy, *see* Percutaneous renal biopsy
- Renal and cardiovascular physiology, 172-179  
 blood pressure measurement and, 173-174  
 cardiac function in, 176-178  
 pressure-natriuresis-diuresis measurements and, 175-176
- Renal changes in HRS, 293-294
- Renal cyclooxygenase 2 (COX2) in progression of renal failure, 410-412
- Renal diseases, *see* Chronic kidney disease; Liver diseases, kidney and; Nephrin in renal disease; Renin-angiotensin aldosterone system, fibrinolysis and, in progressive renal disease and specific renal diseases
- Renal dysfunction, postpartum, in preeclampsia, management of, 60
- Renal failure, *see* Prostaglandin D<sub>2</sub> synthase, progression of chronic renal failure and; Renal failure-associated hypertension
- Renal failure-associated hypertension (HTN), 17-26  
 antihypertensive drug therapy for, 17, 21  
 endothelium in, 22-23  
 GFR and, 17-18  
 HD mode and, 23  
 other factors responsible for HTN, 23-24  
 PTH and hypercalcemia in, 21-22  
 renin-angiotensin-aldosterone system in, 19-20  
 role of salt and water retention in, 18-19  
 sympathetic overactivity in, 20-21
- Renal homeostasis, BNP and, 430-431
- Renal insufficiency, chronic, *see* Anemia in CRI, rHuEPO therapy of

- Renal mediators, *see* Naturally occurring cardiovascular and renal mediators
- Renal osteodystrophy, *see* Percutaneous bone biopsy in ROS; Renal osteodystrophy in CKD
- Renal osteodystrophy (ROS) in CKD, 488-493  
 diagnosis of, 489-491  
 pathophysiology of, 488-489  
 preparation for, 529  
 therapy of, 491-492, 528
- Renal replacement therapy (RRT)  
 HRS management with, 297-298  
*see also specific modes of renal replacement therapy*
- Renal transplantation, *see* Candidate(s) to RTX; Chronic hepatitis B virus infection, RTX and; Hepatitis C virus infection, RTX and and *entries beginning with terms*: Post-renal transplantation, Pre-renal transplantation
- Renal and urinary tract ultrasound, *see* Ultrasound of kidney and urinary tract
- Renal vascular lesions, role of, in renal failure-associated HTN, 23-24
- Renin-angiotensin-aldosterone system (RAAS)  
 in renal failure-associated HTN, 19-20  
 response of, to vasodilation in HRS, 294  
*see also* Renin-angiotensin-aldosterone system, fibrinolysis and, in progressive renal disease
- Renin-angiotensin aldosterone system (RAAS), fibrinolysis and, in progressive renal disease, 399-406  
 and ECM formation regulated by fibrinolytic system, 399  
 effects of, on fibrosis, 401  
 implications of, for therapy, 403  
 PAI-I and, *see* Plasminogen activator inhibitor-1, fibrinolysis and, in progressive renal disease
- Renin-angiotensin system genes in HTN, 116-117
- Reporting on renal and urinary tract ultrasound, 251
- Resin-binding agents, 501
- Resistance, glucocorticoid, HTN in, 46, 49
- Resource utilization, and CKD-associated morbidity in U.S., 444-445
- Respiratory effort, upper airway obstruction due to ongoing, in OSA, 72-73
- RH (radiation hybrid) quantitative trait loci (QTL) mapping in essential HTN, 144
- Rho-kinase, role of, in vascular smooth muscle contractions, essential HTN and, 11
- rHuEPO (recombinant human erythropoietin), *see* Anemia, rHuEPO therapy of
- Ribavirin  
 for chronic HBV infection, 382, 383  
 for HCV infection, 305, 315, 334, 335, 358, 363, 367, 368
- Risk(s)  
 for CVD with CKD, *see* Risk factor(s) for CVD with CKD  
 for HBV and/or HCV infection in HD and PD patients, compared, 353-355  
 of iron replacement in iron-deficiency CKD, 482-485  
 for PRB complications, 264  
 of primary renal disease recurrence after RTX, 518-519  
 of rHuEPO therapy of anemia in CRI, 475
- Risk factor(s) for CVD with CKD, 460-461, 463-469, 494-506  
 abnormal calcium-phosphate metabolism and hyperparathyroidism as, 467-468  
 anemia as, 463-466, 469; *see also* Anemia, rHuEPO therapy of  
 diabetes mellitus and/or hyperglycemia as, 498-499  
 epidemiology of CVD in early stages of CKD and, 494-495  
 hyperhomocysteinemia as, 468, 469, 499-500  
 hyperlipidemia as, 468, 469, 500  
 hypertension as, 466-467, 497-498  
 inflammation as, 468, 469, 501-502  
 IV iron preparations and, 485  
 Lp(a) as, 468, 501  
 proteinuria as, 495-497  
 smoking as, 469, 502  
 stratification of risk for CVD development, 453-454
- ROS, *see* Renal osteodystrophy in CKD
- Routes of transmission  
 of HBV infection in HD patients, 344  
 of HCV infection in PD patients, 355-356
- RRT, *see* Renal replacement therapy
- RTX (renal transplantation), *see* Candidate(s) to RTX; Chronic hepatitis B virus infection, RTX and; Hepatitis C virus infection, RTX and and *entries beginning with terms*: Post-renal transplantation, Pre-renal transplantation
- Ruptured vein, as angioplasty complication, 208-209
- Salicylates, 261
- Salt, *see entries beginning with term*: Sodium
- Saralazine, 298
- Satellite pharmacy in DAC, 239
- Screening  
 for anemia in CRI, 474  
 for CKD in U.S., 446-447  
 serum, for antibodies to HLA phenotypes in pre-RTX evaluation of RTX candidates with CKD, 520  
*see also* Diagnosis
- Sequential dilation of AVF, described, 202
- Serum screening, pre-RTX, for antibodies to HLA phenotypes in RTX candidates with CKD, 520
- Serum creatinine, level of, in U.S. CKD patients, 442-443
- Sex, as determinant of stroke, 129-132
- Sheath selection for angioplasty of AVF and AVGs, 206
- Short tandem repeats (STRs; microsatellites), defined, 106
- Short-term risks of kidney donation, 523
- SHR (spontaneously hypertensive rats), *see*: Cd36 in syndrome X
- Shunt, transjugular intrahepatic portosystemic, for HRS, 297
- Signal transduction, LPA, and mesangial cell proliferation and apoptosis, 418-419
- Signaling cascades for vascular smooth muscle contractions, essential HTN and, 11
- Site  
 angioplasty cannulation, 206  
*see also* Placement, vascular access; Site of catheter insertion
- Site of catheter insertion  
 of chronic PD catheter components, 223  
 of cuffed, tunneled catheters, 211-212  
 thrombosis and, 212
- Skills, *see* Knowledge, skills, and competence in interventional nephrology procedures
- Sleep apnea, *see* Obstructive sleep apnea-related hypertension
- Slit diaphragm, nephrin and, 393-394
- Smoking, as risk factor for CVD in CKD, 469, 502

- Smooth muscle contractions, *see* Vascular smooth muscle contractions in essential HTN
- Snoring, OSA and, 71
- Sodium (Na) channel-related genes, epithelial, in HTN, 117-118
- Sodium (Na) ferrie gluconate supplementation, IV, 481, 482, 484, 485
- Sodium nitroprusside, 67
- Sodium (Na) restriction in HTN  
controversy around, 35-36  
in elderly patients, 67-68
- Sodium (Na) retention  
in HRS, 292-293  
in renal failure-associated HTN, 18-19
- Sonography, *see* Ultrasound in interventional nephrology procedures
- Specimen evaluation  
bone biopsy, 274  
renal biopsy, 260-262
- Spironolactone, 29, 49, 83, 403
- Spontaneously hypertension, *see*: *Cd36* in syndrome X
- Sporadic pheochromocytomas, 95
- Stabilization of CKD, role of comprehensive renal care clinic in, 526-532  
early referral and, 527  
interim results in slowing disease progression, 530-531  
with nutritional support, 528, 529  
and preparation for RTX, 529  
with treatment of complications, 527-528
- Staffing needs of DAC, 229
- Stages  
CKD, 451, 494-495  
initiative ROS, 489
- Starting dose of rHuEPO for anemia of CRI, 476
- Starting points in statistical gene mapping of monogenic traits, 105
- Static venous pressure (VP) in vascular access, measurement of, 190
- Statins, 469, 500-502
- Statistical gene mapping of traits, 105-114  
of complex traits, 110-112  
of monogenic traits, *see* Monogenic traits, statistical gene mapping of
- Stenosis, AVF, 188  
angioplasty for, 202, 203, 206  
site of catheter insertion and, 212
- Stenosis, AVG  
angioplasty for, 204-206  
color flow Doppler ultrasound of, 190-191, 196-198  
site of catheter insertion and, 212  
*see also* Thrombosis, AVG
- Steroids, *see* Corticosteroids; Glucocorticoid(s)
- STR(s) (short tandem repeats; microsatellites), defined, 106
- Stratification of risk for progression of renal disease and cardiovascular disease development in K/DOQI guidelines for CKD, 453-454
- Stress  
HTN prevention with management of, 39  
oxidative, *see* Oxidative stress
- Stroke (cerebrovascular disease), genetics of, 127-134  
epidemiology and twin studies of, 127  
gender determinants of, 129-132  
monogenic forms of, 127-128
- Subcongenic animal lines with essential HTN, 141-143
- Subcortical infarcts and leukoencephalopathy, cerebral autosomal-dominant arteriopathy with, 128
- Subcutaneous vascular ports, as alternatives to cuffed, tunneled catheters, 217-218
- Successful outcome of chronic PD catheters  
catheter burying and, 233  
catheter design and, 227-229  
placement technique effects on, 227
- Successful outcome of interventional nephrology procedures  
of angioplasty for AVF and AVGs, 208  
of PRB, 262  
*see also* Successful outcome of chronic PD catheters
- Supplementation  
Ca, 39, 491, 492  
 $\beta$ -carotene, 58  
folate, 468, 469, 499  
iron, *see* Iron-deficiency anemia in CKD  
K, 37  
Mg, 40  
vitamin A, 469  
vitamin B6 and B12, 469, 499  
vitamin D, 491, 493  
vitamin E and C, 58, 469
- Survival  
of AVF and AVGs, 187  
LPA effects of mesangial cell proliferation and, 417-418  
patient, *see* Patient survival
- Sympathetic nervous system, response of, to vasodilation in HRS, 294
- Sympathetic tone, role of 11 $\alpha$ - and 11 $\beta$ -adrenergic receptors in, HTN and, 119-120
- Sympathomimetic overactivity, HTN and  
in OSA-related HTN, 73-74  
in renal failure-associated HTN, 20-21
- Symptoms  
of pheochromocytoma, 90  
*see also* specific conditions
- Syncytiotrophoblast, role of circulating, in preeclampsia, 59
- Syndrome X, *see*: *Cd36* in syndrome X
- T tests, 3, of cuffed, tunneled catheter insertion, 216
- Terlipressin, 297
- Therapy and management  
of AL amyloidosis and LCDD, 325-327  
of cryoglobulinemia, 314-316  
of HBV infection, *see* Therapy and management of HBV infection  
of HCV infection, *see* Therapy and management of HCV infection  
of HRS, *see* Therapy and management of HRS  
of HTN, *see* Therapy and management of HTN  
immunosuppressive, *see* Immunosuppression in RTX  
of liver involvement in cryoglobulinemia, 314  
OSA, effects of, on HTN, 71-72  
of pheochromocytoma, 96  
of postpartum renal dysfunction in preeclampsia, 60  
of PRB complications, 264  
of progressive renal disease, RAAS implications for, 403

- of ROS, 491-492, 528
- see also* Therapy and management of conditions resulting in CVD with CKD *specific conditions and therapeutic modalities*
- Therapy and management of chronic HBV infection in RTX recipients
  - guidelines on pre-RTX, 380
  - options available for, 3
  - see also specific therapeutic modalities*
- Therapy and management of conditions resulting in CVD with CKD
  - anemia, 463-466, 469; *see also* Anemia, rHuEPO therapy of; Iron-deficiency anemia in CKD
  - hypertension, 466-467
- Therapy and management of HBV infection
  - in GN, 306
  - in HD patients, 347-348
  - preventive, *see* Prevention of HBV infection
  - see also* Therapy and management of chronic HBV infection in RTX recipients *and specific therapeutic modalities*
- Therapy and management of HCV infection
  - with cryoglobulinemic GN, 304-305
  - in HD patients, 334-336
  - see also* Prevention of HCV infection *and specific therapeutic modalities*
- Therapy and management of HRS
  - with liver transplantation, 298
  - medical, 296-297
  - with renal replacement therapy, 297-298
  - with TIPS, 297
  - see also specific therapeutic modalities*
- Therapy and management of HTN
  - in CKD, 466-467
  - in the elderly, 67-69
  - see also* Antihypertensive drug therapy; Diet and lifestyle modification, HTN prevention and management with
- 3 T tests of cuffed, tunneled catheter insertion, 216
- Thrombosis, AVG, 188
  - accuracy of  $Q_a$  measurement and decrease in  $Q_a$  predicting, 191
  - angioplasty for, 204, 205
  - color flow Doppler ultrasound of, 197-198
  - site of catheter insertion and, 212
- Thrombosis, vascular access
  - AVF, angioplasty for, 202
  - in CKD patients, 511
  - site of catheter insertion and, 212
  - see also* Thrombosis, AVG
- Thymopentine, 346
- Time windows, apoptotic, defined, 163
- Tip test of cuffed, tunneled catheter insertion, 216
- TIPS (transjugular intrahepatic portosystemic shunt) for HRS, 297
- Tissue damage, IV iron preparations and, 484
- $\alpha$  (alpha)-Tocopherol (vitamin E) supplementation, 58, 469
- Top test of cuffed, tunneled catheter insertion, 216
- Torsemide, 18
- Total genome scan in apoptosis and proliferation, 165-167
- Training in interventional nephrology, 276-285
  - accreditation and, 277
  - for angioplasty of AVF and AVGs, 209-210
  - certification and, 278; *see also* Certification for interventional nephrology practice
  - competence and, 278
  - for cuffed, tunneled catheter placement, 218-219, 280-281
  - in DAC, 237-238
  - defined, 277
  - hospital or facility credentials and privileges and, 278-280
  - for percutaneous vascular interventions, 281-282
  - for performing renal and urinary tract ultrasound, 251-252
- Traits, *see* Quantitative trait loci mapping of defective *Cd36* in syndrome X; Quantitative trait loci mapping in essential HTN; Statistical gene mapping of traits
- Transgenesis and gene targeting, 154-160
  - additive transgenesis, 154-156
  - cautionary note on, 160
  - gene targeting, 156-159
- Transgenic models, *see: Cd36* in syndrome X
- Transgenic rescue of *Cd36*, effects of, 151
- Transjugular intrahepatic portosystemic shunt for HRS, 297
- Transluminal angioplasty, *see* Angioplasty for AVF and AVGs
- Transmission of infections, *see* Routes of transmission
- Transplantation, *see* Candidate(s) to RTX; Chronic hepatitis B virus infection, RTX and; Hepatitis C virus infection, RTX and; Liver transplantation *and entries beginning with terms*; Post-renal transplantation, Pre-renal transplantation
- Treatment, *see* Therapy and management
- Triamterene, 82
- Tubular necrosis, acute, HRS and, 295-296
- Tug test of cuffed, tunneled catheter insertion, 216
- Tunneled catheters
  - PD catheters, 225
  - see also* Cuffed, tunneled catheters
- Twin studies of stroke, 127
- Type I and II membranoproliferative glomerulonephritis (MPGN) type II, post-RTX recurrence of, 519
- Type II cryoglobulinemia, HCV infection and, 304
- Ultrasound (sonography) in interventional nephrology procedures
  - cuffed, tunneled catheter insertion with, 212-213
  - duplex, of vascular access stenosis, 190
  - PRB with, 257-258
  - see also* Color flow Doppler ultrasound of vascular access; Ultrasound of kidney and urinary tract
- Ultrasound (sonography) of kidney and urinary tract, 242-253
  - equipment used in, 244-246
  - indications for, 242-244
  - interpretation of, 248-251
  - the procedure, 246-247
  - reporting of, and billing for, 251
  - training and certification for, 251-252
- Underfilling hypothesis of Na retention, 292
- Underrecognized condition, CKD as, in U.S., 446
- United States (U.S.), CKD in, 441-448
  - CKD impact on morbidity, 444-445
  - CKD impact on mortality, 445-446
  - prevalence of, 442-444
  - screening for, 446-447
  - underrecognition of, 446
- Upper airway obstruction due ongoing respiratory effort in OSA, 72-73

- Urea recirculation with vascular access, measurements of, 189
- Urinary tract, *see* Ultrasound of kidney and urinary tract
- Vaccination against HBV infection, 344-347, 358, 383
- Vascular access, 183-194  
   with AVFs, *see* Arteriovenous fistulae  
   with AVGs, *see* Arteriovenous grafts  
   blood flow in, *see* Blood flow, vascular access  
   evaluation of, prior to angioplasty, 205-206; *see also* Angioplasty for AVF and AVGs  
   placement of, *see* Placement, vascular access  
   recirculation measurements in, 188-189  
   venous pressure measurements in, 189-190  
   *see also* Catheters; Color flow Doppler ultrasound of vascular access; Dialysis access center; Dialysis access in CKD
- Vascular lesions, renal, role of, in renal failure-associated HTN, 23-24
- Vascular ports, subcutaneous, as alternatives to cuffed, tunneled catheters, 217-218
- Vascular remodeling in HTN  
   defined, 161  
   *see also* Apoptosis and proliferation in HTN
- Vascular smooth muscle contractions in essential HTN, 8-12  
   arachidonic acid in, 10-11  
   Ca<sup>2+</sup>-dependent MLC phosphorylation in, 8-9  
   MAP kinase in, 10  
   mechanisms of, 11-12  
   PKC in, 9-10  
   rho-kinase and signaling cascades in, 11
- Vascular steal syndrome, as dialysis access complication, 512
- Vascular system 3, *see* Cardiovascular system
- Vasoconstrictors for HRS, 296-297
- Vasodilation hypothesis of Na retention, peripheral arterial, 292-293
- Vasodilation in HRS, 294
- Vasodilators for HRS, 298
- Vasopressin analogues, 296-297
- Vein rupture in angioplasty, 208-209
- Venous extravasation, vein rupture and, 208-209
- Venous pressure (VP), vascular access, measurements of, 189-190
- Venous stenosis, *see* Stenosis, AVF; Stenosis, AVG
- Venovenous hemofiltration, continuous, for HRS, 297, 298
- VHL (von Hippel-Lindau) disease, 92-96
- Vincristine, 326
- Virology of HCV infection in HD patients, 332-333
- Vitamin A supplementation, 469
- Vitamin B6 supplementation, 469, 499
- Vitamin B12 supplementation, 469, 499
- Vitamin C (ascorbic acid) supplementation, 58, 469
- Vitamin D supplementation, 491, 493
- Vitamin E ( $\alpha$ -tocopherol) supplementation, 58, 469
- Volume homeostasis, role of BNP in, 430-431
- Von Hippel-Lindau (VHL) disease, 92-96
- VP (venous pressure), vascular access, measurements of, 189-190
- Waiting list for RTX, HCV-infected dialysis patients on, 361-364
- Water retention in renal failure-associated HTN, 18-19
- Weight, *see* Body weight; Weight loss
- Weight loss, HTN prevention with, 37-38
- White-coat hypertension (HTN), effects of biofeedback on, 39
- Y chromosome consomics in stroke, 129-131
- Zinc, 346

